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Abstract 
Dietary fatty acids have surface active properties comparable to substances used as 
absorption enhancers of poorly absorbed drugs. The intestinal epithelium serves as a 
gatekeeping barrier for the absorption of toxic substances, nutrients and drugs. In this 
thesis it is hypothesized that dietary fat might compromise this barrier function of the 
intestinal epithelium. Different absorption pathways in the intestinal epithelium, i.e. the 
paracellular pathway regulated by tight junctions, and the restriction of the active 
transcellular pathway by the efflux transporter breast cancer resistance protein 
(BCRP/ABCG2) were studied. Mannitol and mitoxantrone (MXR) were used as marker 
substances for the respective pathway. Physiologically relevant doses for humans of the 
important dietary fatty acids docosahexaenoic acid (DHA) and oleic acid were used. 
Absorption of cadmium (Cd) and aluminium (Al), relevant in a food contaminant 
perspective, was investigated. 
DHA caused a significantly increased apical to basolateral absorption of mannitol, 
Cd and Al through Caco-2 cell monolayers. Moreover, oleic acid increased absorption 
of mannitol and Al, but not of Cd. As mannitol is a marker for paracellular absorption 
the findings confirm that oleic acid and DHA increase absorption of poorly absorbed 
substances through the paracellular pathway in Caco-2 cell monolayers. Morphological 
analyses with fluorescence microscopy and transmission electron microscopy 
supported these findings. 
Oleic acid increased absorption of MXR both in Caco-2 cell monolayers and in mice. 
In mice, the levels of MXR were increased in blood, intestine, kidney, brain and liver. 
Oleic acid also caused an up-regulation of BCRP gene expression in Caco-2 cells. 
These findings suggest that oleic acid decrease the function of the BCRP mediated- 
efflux of MXR. 
Overall, the results in this thesis have important toxico-kinetic implications for many 
food toxicants normally restricted to be absorbed through the paracellular pathway or 
effluxed by BCRP. The fact that dietary fatty acids increased oral absorption of toxic  
substances is an important finding that ought to be considered in future risk assessment. 
Consequently, risk-based limits for toxic substances may be underestimated if they are 
established in animal studies using diets with low fat content.   
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Do not go where the path may lead; go instead where there is no path and 
leave a trail. 
Ralph, Waldo Emerson, 1803 - 1882 Contents 
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1 Introduction 
The intake of different food constituents, e.g. fat, carbohydrates, proteins, 
vitamins and some trace elements, are essential for life. However, food also 
contains substances that are considered not to have beneficial health effects, 
i.e. substances that can be toxic to the body. It is also known as the basic 
principle of toxicology, stated in the 16
th century by Theophrastus von 
Hohenheim, later Paracelsus, that “the dose makes the poison” or “all things 
are poison, and nothing is without poison, only the dose permits something to 
be poisonous” (Paracelsus 1493 – 1541). With today’s knowledge, these 
statements could for some substances be questioned, for example when no 
threshold of toxicity for a certain effect can be estimated, e.g. mutagenicity. To 
elicit pharmacological, toxicological or nutritive effects a substance has to 
conquer different barriers of the human body to reach the systemic circulation. 
Certain types of food-borne substances, toxic or not, do not easily pass the 
intestinal barrier consisting mainly of the intestinal epithelium. However, 
components in food, such as fatty acids, might increase the absorption of 
certain substances. The consequence of this will be that a substance considered 
as having a low oral toxicity might be unexpectedly toxic as the available dose 
reaching the systemic circulation increases, i.e.”the dose makes the poison”. 
It is well known that certain food components may alter the absorption of 
various drugs in the gastrointestinal (GI) tract, i.e. food is used as a help to 
improve absorption. There even exist guidelines how to perform food 
interaction studies before registration of a drug (Guideline on the Investigation 
of Drug Interactions (EMA, 2012)). Moreover, the pharmaceutical industry use 
surface active substances as excipients in drug products to improve absorption 
of drugs which are normally poorly absorbed through the intestinal epithelium. 
Because the oral route is outstanding for treatment of patients, extensive 
research has been done to find a solution to the problem of poor absorption of 
hydrophilic substances by the oral route. Based on the knowledge from 12 
published pharmaceutical research it has been suggested that fatty acids in 
lipids as well as other surface active substances present in food have the ability 
to enhance absorption of poorly water-soluble toxic and allergenic agents 
(Ilback et al., 2004; Mine & Zhang, 2003; Charman et al., 1997). However, the 
impact of fatty acids on the intestinal barrier permeability has not been 
investigated to any great extent. As a consequence, the impact of dietary fatty 
acids on absorption of toxic substances from food is currently not considered in 
risk assessment of toxic substances.  
Toxicological evaluations of most compounds are based on studies in 
rodents (rats, mice and rabbits) and nonrodents (dogs, pigs) that do not have 
the same diet as humans, i.e. fat content in the animal diets are generally lower 
than in the human diet, except for dogs. The possibility that surface active fatty 
acids in food may influence intestinal absorption of poorly absorbed substances 
may have an impact of the results in toxicity testing. Results from animal 
studies using low-fat diets may underestimate the toxicity in comparison to the 
human situation with high fat diets. A prerequisite for systemic toxicity of a 
substance in the body is that it first has to conquer the protective barrier of the 
intestine.  
In this thesis, it is hypothesized that fatty acids common in food (oleic acid 
and docosahexaenoic acid (DHA)) increase absorption of poorly absorbed and 
food-borne toxic substances by different pathways through the intestinal 
epithelium. First, we investigated the impact of fatty acids on the paracellular 
pathway, which normally only allows small hydrophilic substances to be 
absorbed between the enterocytes. Secondly, we investigated the impact of 
oleic acid on the efflux protein breast cancer resistance protein (BCRP) 
situated at the apical membrane of the enterocytes, preventing substances to be 
absorbed by the transcellular pathway. The results demonstrate that common 
fatty acids in food have an impact on different absorption pathways in the GI 
tract, which ought to be considered in risk assessment of chemical substances 
in food. 13 
2 Background 
This section starts with a description of the GI tract and the absorption 
pathways of substances through the GI tract. Furthermore, lipids in food, the 
occurrence of fatty acids in food and the effects of fatty acids on the intestinal 
epithelium are described. A background is also given to the model substances 
used in the experiments. For simplification in the following text, nutrients, 
drugs or toxicants are cited as substances. 
2.1  The gastrointestinal tract 
Many organs are working in cooperation to digest food. The continuous tube of 
the GI tract (from the mouth to the anus) is 7 to 10 m long. A normally 
working GI tract is shorter due to contraction of muscles in the intestinal wall 
(Gad, 2007). The intestinal epithelium of the small intestine is the main site for 
oral absorption of substances (figure 1). The substance or food will first pass 
into the oral cavity, where it is processed by the teeth, the tongue and the 
digestive enzymes from the salivary glands, before passing through the 
oesophagus via the pharynx to the stomach. The food is processed in the GI 
tract by mechanical and chemical processes. Mechanical digestion starts in the 
mouth by the teeth and further down to the stomach resulting in food that is 
dissolved and thoroughly mixed with digestive enzymes. About 1 litre of food 
can be processed in the stomach at the same time. The acidity of the stomach is 
around pH 3 or lower. The low pH will kill bacteria entering with the food. 
Digestive enzymes will split large molecules such as large carbohydrates, 
lipids, proteins and peptides into smaller molecules (Goodman, 2010). Wave-
like contractions of the smooth muscle in the wall of the GI tract force the food 
onwards. This contraction results in churning of the food and reduces it to a 
soupy liquid called chyme. Not until the food has reached the small intestine 
(duodenum, jejunum and ileum) from the stomach through the pylorus, is it 14 
possible for food toxicants to be absorbed. Digestive enzymes appear along the 
GI tract when food passes the salivary glands, the tongue, stomach, pancreas, 
gallbladder and liver (Binder, 2003). During digestion, approximately 7 litres 
of water, acid, buffers and enzymes are secreted by the cells within the walls of 
the GI tract and by accessory organs into the lumen, each day. The ileum is 
joined to the large intestine by the ileocecal sphincter. In the large intestine, 
water is absorbed and residues from digestion are concentrated before expelled 
as faeces.  
 
 
Figure 1. The major components of the human digestive system. This picture was used with the 
permission from the publisher. Binder H.J., Chapter 40, Organization of the gastrointestinal 
system, Figure 40-1, from the book Medical Physiology, Editors Boron W.F. and Boulpaep E.L., 
first edition, Copyright Elsevier, 2003. A villus and epithelial cells with microvilli, fingerlike 
protrusions at the apical side of the cells, are shown. (Modified by P Aspenström) 
2.1.1  Structure of the small intestinal mucosa, the site of absorption  
The small intestine consists of three parts. Duodenum (25 cm) starts at the 
pyloric sphincter of the stomach, and is followed by jejunum (ca 2.5 m) and 
lastly the ileum (2 to 4 m). In duodenum the acidic content entering from the 
stomach will be neutralized to a pH between 6 and 7. It takes 3 to 4 hours for 
the content to pass through the small intestine (Gad, 2007; Kararli, 1989).  15 
The mucosal epithelium can be considered as a multi barrier, which has to 
be penetrated before the substances can reach the systemic circulation (figure 
2). The epithelium regulates the flow of fluids and solutes between the 
interstitial space and the blood and can also be regarded as a gatekeeper, i.e. it 
controls the entry of nutrients and other substances. 
The first absorptive barrier is the mucus layer, which consists of an outer 
and an inner layer. The inner mucus layer is also known as the unstirred water 
layer or the aqueous boundary layer and contains mostly water and a few per 
cent mucin (Wilson et al., 1971). The glycocalyx, also called the fuzzy coat or 
brush border, is situated just above the enterocytes (figure 2). The glycocalyx 
is a viscous and elastic gel (Reitsma et al., 2007; Kararli, 1989). The inner, rate 
limiting barrier, is the absorptive epithelium, which is lining the GI tract as a 
single layer of columnar cells. 
 
Figure 2. The intestinal barrier layers. (P Aspenström) 
In order to increase the absorptive area of the intestine, the intestinal 
epithelium is folded into tiny finger-like protrusions, which  are called villi and 
are 0.5 to 1 mm long (figures 1 and 2). Each villus is lined by epithelial cells, 
from which protrudes about 1000 microvilli on each epithelial cell, 1m in 
length and 0.1 m in diameter, this is called the brush border. Digestive 
enzymes are produced by the absorptive epithelial cells, and are called brush-
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border enzymes which are then inserted in the plasma membrane of the 
microvilli (Gad, 2007; Kararli, 1989). Due to the villi and microvilli, the 
absorptive area of the human intestine is very large, reaching the size of a 
tennis court of 250 m
2 (Gad, 2007; Le Ferrec et al., 2001; Kararli, 1989).  
The enterocytes of the GI tract are renewed every 5 to 7 days. The 
enterocytes are produced through mitotic division at the basis of the villus in 
the crypt of Lieberkühn, from which the maturing absorptive enterocytes 
continuously migrate up to the tip of the villus. After approximately 3 days the 
enterocytes are discarded into the bulk of the intestine. The tip and the one 
third upper part of the villus is believed to be the main site for absorption of 
substances with high permeability (Gad, 2007; Kararli, 1989; Madara, 1989). 
When the substances are absorbed they reach the blood and then are further 
distributed to various sites (target organs) in the body.  
The intestinal epithelium consists not only of the absorptive enetrocytes. 
There are  three types of secretory cells called entero-endocrine cells (secrete 
hormones and neuropeptides), Paneth cells (located adjacent to the stem cells 
in the crypt of Lieberkühn, and containing antimicrobial compounds important 
for immunity and probably defending epithelial cell renewal) and goblet cells 
(secrete mucus) (Binder, 2003). In addition, there are M cells (transport 
intestinal bacteria and antigens from the lumen to the lymphoid tissues), 
caveolated cells (tuft cells) and cup cells, as well as stem cells (in crypts of 
Lieberkühn) and intraepithelial lymphocytes (Santos & Perdue, 2000). 
However, enterocytes make up to 90 % of the cells in the small intestine (Shah 
et al., 2006; Madara, 1989).  
Adjacent enterocytes are closely attached to each other by junctional 
complexes in the apical membrane, such as tight junctions (TJs,) (zona 
occludens, ZO-1), adherens junctions (zonula adherens or the intermediate 
junction) and the desmosomes (macula adherens) (Vandenbroucke et al., 2008; 
Ballard et al., 1995). These structures define the paracellular space which 
regulates the absorption of substances between the cells trough the paracellular 
pathway (figure 3). 
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Figure 3. Different cell-cell contacts, tight junctions, adherens junctions, desmosomes and GAP 
junctions, between two enterocytes. Some proteins in TJs (ZO-1, Occludin, Claudin1) and in 
adherens junctions (-catenin, E-cadherin) and actin are also shown. (P Aspenström) 
The TJs are composed of multiple proteins, e.g. occludin, claudin 1, E-
cadherin, ZO-1, caterins, actin and cingulin. Catenin is a protein involved in 
the formation of adherens junctions of the epithelium. Furthermore, -catenin 
is necessary for the function of cadherin and its adhesive properties when 
binding to the cytoskeleton. Cadherins constitute a large family of single-pass 
transmembrane proteins principally involved in Ca
2+ dependent cell adhesion 
(Gooding et al., 2004).  
2.2  Absorption of substances through the intestinal epithelium 
When a substance has reached the small intestine, it first has to penetrate the 
mucus layer (Hayashi & Tomita, 2007; Larhed et al., 1997). The plasma 
membrane below the mucus layer consists of a phospholipid bilayer, but it is 
also laterally segregated into different domains, consisting of a dynamic 
accumulation of proteins and lipids of different types. Among these are small 
(10 – 200 nm) sphingolipid- and cholesterol-enriched insoluble lipid rafts or 
membrane microdomains, important for cell signalling and intracellular lipid 
and protein movement (Aye et al., 2009; Hayashi & Tomita, 2007; Storch et 
Desmosomes
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al., 2007; Simons & Ikonen, 1997). The lipid rafts are tightly packed, which 
results in reduced fluidity as compared to the fluidity of the surrounding 
membrane. TJ permeability might be attained by e.g. altering the lipid 
composition of the cellular membrane or TJ-associated lipid rafts (Deli, 2009). 
Intestinal absorption is the passage of substances through the intestinal 
epithelium to the circulatory system. There are different pathways for a 
substance to be absorbed through the intestinal epithelium (Goole et al., 2010; 
Artursson et al., 2001). The characteristics of each substance determine the 
way it is absorbed, i.e. its size, charge or solubility, the structure of the 
substance, as well as if it is hydrophilic or lipophilic. Absorption can be either 
passive or active. Passive transport is driven by a concentration gradient and 
active transport requires energy (figure 4). Energy is obtained by hydrolysis of 
adenosine triphosphate (ATP) to adenosine diphosphate (ADP), resulting in 
energy release from the phosphate bond (Goole et al., 2010; Batrakova et al., 
2004). Three different transport processes contribute to the absorption of 
substances (figure 4). Transcytosis is a vesicle-mediated pathway across the 
enterocytes (Vandenbroucke et al., 2008) (figure 4D). It is mostly large 
molecules such as proteins and peptide antigens that are absorbed through this 
pathway and they are mostly broken down by enzymes in the vesicles during 
the passage. The other two pathways are the paracellular and transcellular 
pathways (figure 4 A, B and C). 
 
Figure 4. A substance can be absorbed through the enterocytes by different pathways. A) passive 
transcellular, B) active transcellular, C) passive paracellular and D) transcytosis. (P Aspenström) 
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2.2.1  Passive absorption through the paracellular pathway  
Cell membranes are lipophilic which means that they are nearly impermeable 
to hydrophilic substances. The absorption of small hydrophilic substances 
therefore often takes place through the paracellular pathway (figure 3 and 4C). 
As described above, intestinal epithelial cells are closely attached to each other 
at the apical side of the enterocyte with TJs (figure 3). TJs surround each cell 
of the intestinal epithelium (Watson et al., 2001). Only small or medium 
molecular weight, hydrophilic molecules, is absorbed through this pathway by 
passive diffusion (Vandenbroucke et al., 2008; Artursson et al., 2001). 
Absorption is quite limited, since the paracellular pathway comprises a very 
low percentage of the total epithelial surface area (Artursson et al., 2001). To 
study TJ permeability in vitro the cell line Caco-2 is commonly used. Caco-2 
cells are further described in the section Material and Methods. 
TJs contain pores with different sizes and different charge specificities 
(Linnankoski et al., 2010; Van Itallie et al., 2008; Watson et al., 2005). TJs 
appear to be cation selective as these ions of weak bases permeated the 
aqueous pores at a faster rate than anions of weak acids (Pade & Stavchansky, 
1997)  The pores can multiply in both small and large pores or grow larger in 
size, i.e. increase the pore radius. The pore radius of the very small pores is of 
the size of 4 Ångström (Å). Two pore sizes (5-6 Å and >10Å) have been found 
in the human intestinal epithelium and in Caco-2 cells (Linnankoski et al., 
2010). However, the paracellular porosity of the intact human intestinal 
epithelium is 10 times higher than in the Caco-2 cells. The number of pores 
was found to be much higher in the human intestine than in the Caco-2 cell 
monolayers, which could partly explain a lower permeability in these cells 
compared to the human intestinal epithelium. Watson et al., 2001, investigated 
the permeability of 24 polyethylene glycols (PEG) of increasing molecular 
radius (3.5 – 7.4 Å) in Caco-2 cells (Watson et al., 2001). They found both a 
restrictive pore (4.3 – 4.5 Å) and a non-restrictive pore, which was responsible 
for permeability of larger molecules. Sodium caprate (C10) which is a fatty 
acid with 10 carbons in the carbon chain, had no effect on pore radius but 
increased permeability in another way, probably by increasing the number of 
functional pores. Ethylene glycol tetra-acetic acid (EGTA) treatment resulted 
in that cells lost all size discrimination due to increased pore size (Watson et 
al., 2001).   
TJ proteins at the apical cellular membrane, such as occludin and ZO-1, are 
dependent on the presence of Ca
2+ for their function (Vandenbroucke et al., 
2008; Collares-Buzato et al., 1994). TJs are opened through contraction of 
actin and myosin filaments and endocytosis of the transmembrane protein 
cadherin, a process that also requires Ca
2+ (Hayashi & Tomita, 2007).  20 
The TJ barrier is dynamic and can be modulated by both intracellular and 
extracellular events. Substances in food might alter or disrupt the tight 
junctions and in that way increase the absorption of toxic substances in food 
through the paracellular pathway.  
2.2.2  Transcellular absorption across the intestinal epithelium 
The transcellular pathway from the intestinal lumen to the circulatory system 
starts with the absorption of a substance through the lipid bilayer of the apical 
membrane of the enterocytes, followed by transport through the cytosol to the 
basolateral side of the membrane of the enterocytes and finally through the 
membrane into the circulatory system. The transport can be passive or active or 
both.  
Passive transcellular pathway 
Substances have to partition from the luminal fluid into the apical membrane of 
the epithelial cells before a concentration gradient driven passive diffusion 
takes place (figure 4A). As the cell membrane consists of lipids/phospholipids, 
it is mainly lipophilic substances that can be considered for this pathway. As 
the absorption area of the plasma membranes of the enterocytes are larger than 
the absorption area of the TJs, some of the expected absorption via TJs might 
take place by the passive transcellular pathway (Artursson et al., 2001). 
However, the active carrier mediated transport is saturable and when this 
occurs substances may be absorbed through the passive transcellular route. So 
the absorption transcellularly can be partly active and partly passive (Sugano et 
al., 2010; Shah et al., 2006).  
 
Active transcellular pathway  
Membrane transporters have a great impact on the kinetics in the body of toxic 
substances and drugs but also of essential nutrients. The active transcellular 
pathway is mediated through transporter proteins, which function either as 
efflux transporters or as uptake transporters (figure 4B and 5) (Ni et al., 2010; 
Rosenberg et al., 2010; Hayashi & Tomita, 2007; Xia et al., 2005). The 
location of many uptake and efflux transporters is at the apical side of the 
enterocytes, facing the lumen of the GI tract. They also reside on the 
basolateral side of the enterocyte, facing the blood (Giacomini et al., 2010). 
The transporter proteins belonging to the ATP binding cassette (ABC) 
family and the solute carrier (SLC) superfamily consists of more than four 
hundred membrane transporters in humans (Giacomini et al., 2010; Anderle et 
al., 2004). The uptake transporters, belonging to the SLC superfamily, do not 21 
need energy as they transport their substrates according to the concentration 
gradient (Giacomini et al., 2010; Oostendorp et al., 2009). The SLC 
superfamily contains among others, the organic anion transporting 
polypeptides transporters (OATPs), organic cation transporters (OCTs) and 
also metal transporters.  
Apical efflux transporters actively extrude substances from the epithelial 
cells to the intestinal lumen, and thereby reduce absorption into the systemic 
circulation, both parent substances and metabolic products.  
The ABC family of membrane transporters functions as ATP-dependent 
active membrane transporters, translocating molecules across a cell membrane 
against a concentration gradient and thereby reducing their intracellular 
concentration. There are three main transporters with important clinical 
relevance, i.e. breast cancer resistance protein (BCRP; ABCG2, discovered 
1998), multidrug resistance protein 2 (MRP2; ABCC2, discovered 1992), and 
permeability-glycoprotein (P-gp; MDR1, ABCB1, discovered 1976) (Doyle & 
Ross, 2003). 
 
Figure 5. Examples of transporter proteins residing both at the apical side and the basolateral side 
of the enterocytes. Apically: the efflux transporters BCRP (ABCG2), P-gp (ABCB1), MRP2 
(ABCC2), the fatty acids uptake transporter FABP, and the solute carriers DMT1, ZIP8, ZIP14 
and OATP. Inside the enterocyte: the fatty acid transporter protein FATB and the metal binding 
protein, metallothionein MT. Basolaterally: Cd efflux transporter MRP1 and solute transporter 
OCT. (P Aspenström) 
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BCRP, P-gp and MRP2 are all present in the human intestinal epithelium at the 
apical side of the membrane facing the lumen (Goole et al., 2010; Ni et al., 
2010; Rosenberg et al., 2010; Aye et al., 2009). Most functional ABC 
transporters consist of two ATP-binding domains and two sets of 
transmembrane domains (Doyle & Ross, 2003). ABC transporters have two 
sets of hydrophobic segments that cross the membrane and which are thought 
to assign all or most of the specificity of the transporter (Robey et al., 2009). 
Some transporters function as metal ion uptake transporters and belongs to 
the SLC family of transporters, e.g. divalent metal transporter 1 (DMT1) and 
the zink and iron transporter proteins (ZIP 8 and ZIP 14) (Fujishiro et al., 
2012). DMT1 is situated at the apical membrane and is primarily regarded as 
iron (Fe) transporter. However, it has been shown that it is an uptake 
transporter for nickel (Ni), cadmium (Cd) as well as other divalent metals 
(Tallkvist et al., 2001).  
During the last 40 years several efflux transporters have been identified of 
which P-gp was the first (Doyle & Ross, 2003). Three models for the efflux 
action of P-gp has been suggested (Constantinides & Wasan, 2007). In the pore 
model, substances connect with P-gp in the cytosolic compartment and are 
transported out through a protein channel. In the flippase model, P-gp flips 
drugs from the inner leaflet of the plasma membrane to the outer leaflet against 
a concentration gradient. Finally, in the hydrophobic vacuum cleaner model, 
intra membranous molecules which do not belong to the membrane, are 
recognised by P-gp and enter P-gp from the membranous side and leave the 
cell. Only sparse information of the mechanisms for the efflux action of BCRP 
has been found. The flip flop mechanism has been described for BCRP where 
the substrate was flip flopped from the outer to the inner leaflet of the cells 
(Breuzard et al., 2007; Matsson et al., 2007). It could be speculated that the 
same mechanisms as for P-gp are valid for BCRP as well.  
P-gp has been important in the preclinical evaluation of ivermectin. It is one 
of the most used drugs in the world as it is important for treatment of parasitic 
infestations in humans and in animals. The Joint FAO/WHO Expert   
Committee on Food Additives (JECFA) based the acceptable daily intake 
(ADI) for ivermectin on the results from a mouse strain (Mdr1a-/- mice) that 
had a 100-fold higher sensitivity to ivermectin than other mouse strains 
(Schinkel et al., 1994; JECFA, 1993). This effect was shown to be due to lack 
of P-gp in the blood-brain barrier in this mouse strain, resulting in neurological 
effects and death. A lack of P-gp has also been found in certain dog species 
e.g. collie (sheepdogs). However, recently it has been found that ivermectin is 
also a substrate for BCRP (Matsson et al., 2009; de Vries et al., 2007). This 23 
illustrates that several efflux proteins can be involved and overlapping each 
other for a substance.  
Breast cancer resistance protein (BCRP)  
BCRP is an ABC transporter and is the second member of the subfamily G, i.e. 
ABCG2. It has a pivotal role for absorption, distribution and excretion of drugs 
and potentially toxic substances that may be present in food (tables 1 and 2). 
During the 1990-ies
  a number of cell lines without overexpression of the 
known efflux transporters P-gp and MRP1, were found. These cell lines were 
resistant to mitoxantrone (MXR) (Doyle & Ross, 2003; Doyle et al., 1998). 
One of the cell lines was derived from a resistant breast cancer cell-line and 
was called BCRP.  
BCRP is a 75 kDa polytopic plasma membrane protein that consists of 655 
amino acids. It is a half transporter with one transmembrane domain (TMD) 
and one nucleotide-binding domain (NBD). BCRP has to dimerize to function 
properly (Planas et al., 2012; Giacomini et al., 2010; Ni et al., 2010; 
Wakabayashi et al., 2006). BCRP has an amino acid sequence which is closely 
similar to one-half of the duplicated P-gp molecule. The ABCG2 gene is highly 
conserved and has been found in all sequenced vertebrates, including birds, 
reptiles, and fish.  
 Since the discovery of BCRP a tremendous amount of research has been 
done to find inhibitors and substrates for this efflux-transporter. BCRP 
performs energy-dependent efflux of a large number of compounds that are not 
structurally or chemically related (see table 1 and 2). BCRP is highly expressed 
in organs important for absorption (small intestine), elimination (liver and 
kidney), and distribution (the blood-brain and placental barriers) of drugs and 
xenobiotics and thereby influences the kinetics of substances and protects the 
body from unwanted substances (Matsson et al., 2007; Gutmann et al., 2005). 
It may also provide xenobiotic protection in stem cells (Robey et al., 2009; 
Staud & Pavek, 2005). One physiological role of BCRP is likely to provide 
tissue protection against endogenous compounds as dietary flavonoids, heme, 
porphyrins, riboflavin, and estrogens. 
Polymorphism in the BCRP gene results in inter-individual variations in the 
pharmacokinetic response, as well as in toxicity, caused by drugs. Inter-
individual differences in BCRP function probably contribute to variable 
pharmacological responses of drugs that are BCRP substrates (Giacomini et 
al., 2010). As some substances are inhibitors and some are substrates for BCRP 
it is possible that simultaneous exposure of BCRP inhibitors and substrates will 
alter the fate and toxicity of numerous drugs, carcinogens and toxicants present 
in food. 24 
Surprisingly, BCRP is also situated in the apical membranes of mammary 
epithelial cells of the breast during lactation where it efflux substances into the 
milk in both humans and cows (van Herwaarden & Schinkel, 2006; Jonker et 
al., 2005; Maliepaard et al., 2001). Consequently, the suckling infant and milk 
drinkers may be exposed to toxic BCRP substrates through milk. A reason for 
this function may be to supply the infant with substances needed for growth 
and development like the BCRP substrates vitamin B2 (riboflavin), folic acid, 
vitamin K and possibly biotin (Robey et al., 2009; van Herwaarden et al., 
2006). It could also be speculated that BCRP has a detoxifying function for the 
mother on expense of the health of the newborn, i.e. the survival of the mother 
is most important in an evolutionary perspective.  
The expression of BCRP in the intestine of humans is highest in the 
duodenum, and then descending through the jejunum and ileum to colon 
towards the rectum (Gutmann et al., 2005). In mice, the expression of BCRP 
do not follow the same pattern, i.e. it peaks in the ileum, followed by the 
jejunum and duodenum and then decreasing towards the rectum (Enokizono et 
al., 2007b; Han & Sugiyama, 2006; Tanaka et al., 2005).  
BCRP is important in the protection of internal organs from a wide range of 
toxic substances that can be present in food, such as dietary carcinogens like 
heterocyclic amines formed during frying e.g. PhIP (2-amino-1- methyl-6-
phenylimidazol[4,5-b]pyridine) and mycotoxins (ochratoxin and aflatoxin B1) 
(tables 1 and 2). BCRP has alo been shown to efflux trans-resveratrol 3- 
glucuronide which is a polyphenol from plants believed to have beneficial 
effects on certain diseases in humans (Planas et al., 2012). Moreover, it is also 
an efflux transporter for many drugs used in human medicine (mitoxanthrone, 
estrone-3-sulfate (E1S), nitrofurantoin, cimetidine) and in veterinary medicine 
(e.g. fluoroquinolones as enrofloxacin, ciprofloxacin, ivermectins).   
Nuclear receptors (NR) regulate the expression of several ABC transporters 
(Chawla et al., 2001; Schinkel et al., 1994). NRs are transcription factors that 
function as modulators of tissue gene expression. There are forty nine members 
of the NR superfamily known. The mRNA expression of BCRP was directly 
and specifically regulated by the peroxisome proliferator activated receptors  
(PPAR in monocyte-derived human dendritic cells (Vlaming et al., 2009). 
The increased gene expression of BCRP results in higher levels of the BCRP 
protein, which subsequently increases the capacity of cells to extrude toxic 
substances. This is a mechanism for cancer cells acquiring resistance against 
e.g. anticancer drugs (cytostatica). Seven transporters, BCRP, Abcd3 and five 
SLC transporters, expressed in the mouse intestine, were found to be up-
regulated by PPAR (Hirai et al., 2007). Thus, it seems reasonable to assume 
that BCRP is up-regulated by both the PPAR and PPAR nuclear receptors. 25 
Furthermore, expression of BCRP has also been shown to be dependent of the 
transcription factor, aryl hydrocarbon receptor (AhR). Known AhR agonists 
like 2,3,7,8-tetrachlorodibenzo-p-dioxin and benzo[a]pyrene (BP), indolo[3,2-
b]carbazole increased both mRNA and protein levels of BCRP in Caco-2 cells 
(Tan et al., 2010; Ebert et al., 2005).  
Table 1. Some inhibitors of BCRP (not necessarily restricted to BCRP) 
Substance References 
Present in food 
Chrysin 
Curcumin (polyphenol) 
Fumitremorgin (FTC)  
Drugs 
Geftinib (human drug) 
Triclabendazole (veterinary drug) 
Special synthetic inhibitors 
Ko143 (analogue to FTC) 
Elacridar (GF 120918) 
 
(Mao & Unadkat, 2005; Zhang et al., 2004b) 
(Kusuhara et al., 2012; Zhu et al., 2010);  
(Matsson et al., 2009; Allen et al., 2002) 
 
(Zaher et al., 2006) 
(Barrera et al., 2012) 
 
(Matsson et al., 2009; Xia et al., 2005; Allen et al., 2002) 
(Durmus et al., 2012) 
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Table 2. Some substrates for BCRP relevant from a food safety point of view and some human 
drugs which are substrates for BCRP are shown below. Substances may be both inhibitors and 
substrates and some may also be substrates or inhibitors for other transporter proteins.  
Substance  
Present in food 
Substances in coffee (depending on 
roasting time) 
Benzo[a]pyrene 
 
BisphenolA 
PhIP (2-amino-1-1methyl-6-
phenylimidazol[4,5-b]pyridine) 
Mycotoxins (ochratoxin, 
aflatoxin B1) 
Phytoestrogens 
Flavonoids (e.g. genistein sulphate, 
chrysin) 
trans-Resveratrol 3-glucuronide 
 
Veterinary drugs 
Benzimidazoles (e.g. albendazole, 
albendazole-sulfoxide, 
oxfendazole) 
Ivermectin 
 
Fluoroquinolones (enrofloxacin, 
ciprofloxacin)  
 
Human drugs and metabolites 
Methotextrate (MXT) 
Mitoxantrone (MXR) 
 
 
Topotecan 
Diclofenac 
Cimetidine 
Estrone-3-sulfate (E1S) 
17-estradiol-glucuronide 
Nitrofurantoin 
 
Endogenous and essential 
substances 
Riboflavin 
Folic acid 
Progesterone 
 
(Isshiki et al., 2011) 
 
(Hessel & Lampen, 2010; Ebert et al., 2007; Ebert et al., 2005; 
van Herwaarden et al., 2003) 
(Mazur et al., 2012; Ebert et al., 2005) 
(Pavek et al., 2005; van Herwaarden et al., 2003) 
 
(van Herwaarden et al., 2006) 
 
(Zhu et al., 2010; Enokizono et al., 2007a; Zhang et al., 2004a) 
(Pick et al., 2011; Kawase et al., 2009; Zhang et al., 2005; 
Zhang et al., 2004a) 
(Planas et al., 2012) 
 
 
(Haslam et al., 2011; Alvarez et al., 2008; Merino et al., 2006; 
Merino et al., 2005a) 
 
(Jani et al., 2011; Real et al., 2011; Merino et al., 2009; de 
Vries et al., 2007) 
(Real et al., 2011; Matsson et al., 2009; Alvarez et al., 2008; 
Merino et al., 2006; Pulido et al., 2006) 
 
 
(Xia et al., 2005) 
(Aspenstrom-Fagerlund et al., 2012; Gram et al., 2009; Matsson 
et al., 2009; Yamagata et al., 2009; Yamagata et al., 2007a; 
Zhang et al., 2005; Zhou et al., 2005) 
(de Vries et al., 2007; Kruijtzer et al., 2002; Jonker et al., 2000) 
(Lagas et al., 2009) 
(Pavek et al., 2005) 
(Gram et al., 2009) 
(Mao & Unadkat, 2005) 
(Kawase et al., 2009; Merino et al., 2005b) 
 
 
 
(van Herwaarden et al., 2007) 
(Assaraf, 2006; Breedveld et al., 2005) 
(Matsson et al., 2009; Vore & Leggas, 2008) 27 
2.3  Lipids in food 
Michel Eugène Chevreul (1786 – 1889) was the first to discover the structure 
and properties of lipids. He showed that fat is generally a combination of fatty 
acids and glycerol forming triglycerides, and he described the structure of oleic 
acid, butyric acid, capric acid, stearic acid, cholesterol and glycerol. In 
addition, he found that lard contained solid fat which he called stearine. A 
liquid phase of the fat was called elaine, which was shown to be an isomer of 
oleine (oleic acid). All this was published in 1823, in “Recherches chimiques 
sur les corps gras d’origine animale” (Costa, 1962). 
Dietary fat is essential for all living organisms, including humans, as a main 
nutrient for growth and development. It provides energy, function as a store 
and reservoir for lipoprotein trafficking, is important for bile acid synthesis, 
stereoidogenesis and is also a structural component in cells, e.g. in the cell 
membrane (Iqbal & Hussain, 2009). Fatty acids also regulate gene expression 
for nuclear receptors and transporters.  
In a balanced diet about 30 to 35 % of the energy (E %) consist of fat and 
more than 90 % of the dietary fat comprises triacylglycerol (TAG) or 
triglycerides (EFSA Panel on Dietetic Products, 2010). In Sweden the intake of 
fat is 34.2 E %, based on Riksmaten 2012 (National Food Agency, 2012). 
Phospholipids, sterols (e.g. cholesterol), and other lipids (e.g. fat soluble 
vitamins) are the remaining constituent in dietary fat (Ratnayake & Galli, 
2009). TAG consists of three fatty acids connected to a glycerol molecule with 
ester bonds (figure 6). The most common fatty acids in food are long chain 
fatty acids (>12 carbons) (Goodman, 2010).  
 
Figure 6. Triglyceride with linoleic acid (C18:2) at the top, linolenic acid (C18:3), in the middle 
and oleic acid (C18:1) at the bottom. 
2.3.1 Fatty  acids   
A fatty acid consists of a carbon chain starting with a carboxyl group at one 
end and a methyl group in the other end. Fatty acids are divided in groups of 28 
different chain lengths. The short-chained fatty acids have 3 to 7 carbons, the 
medium-chained fatty acids have 8 to 13 carbons, and the long-chained fatty 
acids have 14 or more carbons (Ratnayake & Galli, 2009). Saturated fatty acids 
(SFA) are devoid of any double bond between the carbons in the carbon chain. 
There are also monounsaturated fatty acids (MUFA) with one double bond and 
polyunsaturated fatty acids (PUFA) with several double bonds. When the first 
double bond is situated at the third, sixth or ninth carbon from the methyl 
group, the fatty acid belongs to the Ω-3, Ω-6 or Ω-9 fatty acids (Ratnayake & 
Galli, 2009). The melting point of fatty acids decreases with increasing number 
of double bonds and the reactivity increases with increasing number of double 
bonds. The body lacks enzymes for desaturation of double bonds at position 3 
and 6, which means that these fatty acids are needed from the diet, i.e. essential 
fatty acids. The parent fatty acid from the Ω-3 family is α–linolenic acid [18:3] 
and from the Ω-6 family it is linoleic acid [18:2]. However, the body is able to 
endogenously produce SFA and indirectly Ω-9 fatty acids, by synthesis from 
carbohydrates (Ratnayake & Galli, 2009).  
In addition to the involvement in cell structure and energy supply, dietary 
fat has a great impact on gene expression, regulating metabolism, growth and 
cell differentiation (Jump, 2004; Chawla et al., 2001; Jump & Clarke, 1999; 
Jump et al., 1997). Several members of the NR super family have been found 
to be fatty acid receptors, among others the PPARs (Khan & Vanden Heuvel, 
2003; Jump & Clarke, 1999). Several mono- and polyunsaturated fatty acids 
bind to PPARα at physiological concentrations and cause transcriptional 
activation (Hirai et al., 2007; Khan & Vanden Heuvel, 2003; Chawla et al., 
2001).  
Metabolism of lipids in the GI tract  
Triglycerides are digested in the intestine to mono-, di- and triglycerides and 
free fatty acids (FFA). The cooking of food, chewing of food, and churning 
and peristalsis in the stomach facilitate the formation of an emulsion of the 
triglycerides. Emulsification of dietary fat also involves lingual and gastric 
enzymes, but only approximately 15% of the fat is digested in the stomach 
(Iqbal & Hussain, 2009). Crude emulsion of fine lipid droplets mainly 
containing triglycerides, reach the duodenum, where they are further 
hydrolysed by pancreatic lipases. The hydrolysis, mediated by pancreatic 
lipases, starts with the first and third fatty acid chain at the glycerol molecule, 
leaving two free fatty acids and one 2-monoacylglyceride (2-MAG) 
(Goodman, 2010). During the hydrolysis, emulsion droplets dissociate into 
micelles with the help of bile salts (Goodman, 2010). These micelles are 
carried across the unstirred water layer above the brush border membranes of 29 
the enterocytes. The mixed micelles then reach the lipid bilayer in the apical 
membrane of the enterocytes, where the fatty acids are either protonated and 
leave the mixed micelle to diffuse across lipid bilayer membranes, or become 
provisionally a cell membrane lipid.  
Different mechanisms have been suggested for the uptake and transport of 
long-chained fatty acids across the apical membrane of the enterocytes. One is 
the protein-independent diffusion model and another is a protein-dependent 
mechanism (Iqbal & Hussain, 2009). One important protein for the uptake of 
fatty acids in the enterocyte is the fatty acid translocase (FAT or FAT/CD36), 
which is expressed in the intestinal epithelium. The presence of dietary fat as 
well as genetic obesity and diabetes, results in an up-regulation of FAT. 
Furthermore, the fatty acid transporters FATP2 (SLCA272) and FATP4 
(SLCA274) have been found to be expressed in the small intestine (Goodman, 
2010; Iqbal & Hussain, 2009; Mu & Hoy, 2004). The fatty acid-binding protein 
family (FABP) is tissue specific and is situated in many tissues, and also in the 
brush border membrane of the enterocytes. The FABPs has high affinity for 
binding of long-chain fatty acids and may play a role in the uptake of fatty 
acids (Storch & Thumser, 2010). Once inside the enterocytes long chained 
fatty acids and MAG are carried by the fatty acid transport protein (FATP) and 
cross the cytoplasm to the smooth endoplasmatic reticulum for reconstitution 
to form triglycerides (TAG). Several enzymes take part in this synthesis to 
TAG (Iqbal & Hussain, 2009; Mansbach & Gorelick, 2007). After the fatty 
acids have been re-synthesized to TAG in the enterocyte they are assembled 
with proteins and phospholipids into chylomicrons. Several transport proteins 
are involved in this process. Finally, the chylomicrons are expelled across the 
basolateral membrane to the lymph vessels in the core of the villus by 
exocytosis and the TAG enters the bloodstream via the thoracic duct, the 
largest lymphatic vessel in the body.  
Surface activity of fatty acids 
Fatty acids have different characteristics depending on carbon length and 
number of double bonds. The number of carbons, as well as the number of 
double bonds, is important for the surface activity of fatty acids (Mao & 
Unadkat, 2005). Fatty acids, like other surface active substances, have a 
lipophilic part and a hydrophilic part. The hydrophobicity of fatty acids 
increases with carbon chain length. This is consistent with Traube’s rule which 
states: “in dilute aqueous solutions of surfactants belonging to any one 
homologous series, the molar concentrations required to produce equal 
lowering of the surface tension of water decreases threefold for each additional 
CH2 group in the hydrocarbon chain of the solute“ (Attwood, 2006).  30 
2.3.2  Intake of fatty acids through the diet 
Saturated fat on average represents about 13 E % of the Swedish diet or  40 E 
% of the total fat, as a component in hard margarines, butter, meat and dairy 
products (Livsmedelsverket (2012); Becker & Pearson, 2002). Palmitic acid 
[C16:0] and stearic acid [C18:0] is quantitatively the most important of the 
saturated fatty acids (SFA). 
Monounsaturated fatty acids (MUFA) represents approximately 12.8 E % of 
the total diet and 39 E % of the total fat in food (Livsmedelsverket (2012)). 
The quantitatively most important MUFA is oleic acid [C18:1], which can be 
found in milk fat and vegetable oils up to 71% (EFSA Panel on Dietetic 
Products, 2010).  
Polyunsaturated fatty acids (PUFA) represents approximately 5.6 E % of 
the total diet or 14 E % of the total fat in the diet (Livsmedelsverket (2012)). 
The PUFA’s are essential fatty acids that are present in vegetable oils, soft 
margarines and fish oils.  Ω-3 fatty acids is found in linseeds, rapeseed oil and 
walnuts, fish, human milk and marine algae (EFSA Panel on Dietetic Products, 
2010). The most commonly discussed Ω-3 fatty acids are docosahexaenoic 
acid (DHA), with an average intake of 0.4 g/day, and eicosapentaenoic acid 
(EPA), with an average intake of 0.2 g/day.  
2.3.3  Fatty acids used in the thesis 
In our studies we have used oleic acid and DHA. Oleic acid was used because 
it is the most common MUFA in food, whereas DHA is interesting in a health 
perspective, i.e. it is sold as Ω-3 food supplement that contains high amounts 
of DHA and EPA.  
Oleic acid  
 
Figure 7. Oleic acid (C18:1, n=9) Mw 282.5 
Oleic acid is the most common fatty acid in food, in Sweden, with a 
contribution of approximately one third of the total intake of fat (Becker & 
Pearson, 2002). It is present in both plant and animal derived foods (including 
fish), in seed, avocado, nuts, milk fat (21 mg/100g), olive oil (71.3 mg/100g), 31 
and a lot of other vegetable oils (Rose & Connolly, 1999). Oleic acid can be 
synthesised by mammals. 
Oleic acid has been associated with a positive effect on stroke and coronary 
heart disease (Samieri et al., 2011; Waterman & Lockwood, 2007). It has also 
been shown that olive oil induces its beneficial effect on blood pressure 
through oleic acid (Teres et al., 2008). Olive oil is also believed to reduce the 
incidence of cancers of the breast, skin and colon (Owen et al., 2004).  
The typically daily intake in Sweden of MUFA (oleic acid) has increased 
during 2005 to 2010 from approximately 39.1 to 42.1 g/person daily based on 
data from a market food basket (Livsmedelsverket (2012)). Based on data from 
a population-based food consumption survey, Riksmaten 2010 -2011, an 
average daily intake of  24.2 g (woman) to 30.2 g (male) of oleic acid was 
estimated, corresponding to 85.6 - 107 mmol a day or 28.5 – 35.6 mmol/meal 
(National Food Agency, 2012). The actual oleic acid level in the intestine 
depends on the volume of the stomach content at the time of intake. A volume 
of 0.1 litres to 1 litre in the stomach after a meal would on average result in 
oleic acid levels ranging from 285 - 356 mM to 28.5 – 35.6 mM. As described 
above, pancreatic lipase in the duodenum hydrolyses fatty acids at position 1 
and 3 in the TAG, leaving 2 fatty acids and one monoglyceride (Goodman, 
2010). Consequently, after ingestion of for instance 28.5 mM oleic acid bound 
in triglycerides, approximately 19 mM will be hydrolysed to free fatty acids in 
the GI tract.  
Docosahexaenoic acid (DHA)  
 
 
Figure 8.  DHA (C22:6, n=3), Mw 328.5 
DHA belongs to the Ω-3 fatty acids. It is found in fish, shellfish, marine algae, 
marine mammals, human milk, egg and liver. It cannot be synthesised by 
mammals and must therefore be solely obtained from the diet, which means 
that it is an essential fatty acid (Rose & Connolly, 1999). However, new 
knowledge challenges this suggesting that DHA and EPA can be synthesized 
from the essential fatty acid α-linolenic acid (C18:3) (Ratnayake & Galli, 
2009). DHA and EPA are involved in many physiological processes, e.g. 32 
modulation of inflammation, platelet aggregation, immune responses, cell 
growth and proliferation, and contraction and dilation of smooth muscle cells 
(Ratnayake & Galli, 2009). A protective role of Ω-3 fatty acids in cancer 
development has also been discussed (Rose & Connolly, 1999). 
Adverse effects of high intakes of DHA and EPA have been reported as 
bleeding episodes, impaired immune function, impaired lipid and glucose 
metabolism and increased lipid oxidation (EFSA Panel on Dietetic Products, 
2012). Based on benefits to reduce cardiovascular disease risk, the EFSA panel 
recommended daily doses between 0.25 to 0.5 g of EPA and DHA. However, 
in contrast to this the panel is also of the opinion that supplemental intakes of a 
combination of DHA and EPA up to 5g daily would not cause safety-related 
problems for the adult population. In addition, supplemental intakes of 1 g 
DHA alone/day were estimated to not give safety concerns in the general 
population.  
The typically daily intake in Sweden of PUFA has increased between 2005 
and 2010 from approximately 14.2 to 15.3 g/person and day based on data 
from a market food basket (Livsmedelsverket (2012)). The Ω-3 fatty acids 
comprised 21.6% of the total PUFA intake, or 3.3 g/person a day. The intake of 
-linoleic acid, which is the parent fatty acid of the long-chained Ω-3 fatty 
acids in the body, is presently 2.6 g/person/day (National Food Agency, 2012). 
The mean intake of DHA between 1997 and 1998 was 0.21 to 0.24 g/day for 
females and males, respectively (Becker & Pearson, 2002). Consumption of a 
meal of 100 g farmed rainbow trout resulted in an intake of 3 mmol DHA (1 
g/100 g) and 1.7 mmol (0.5 g/100g) EPA (Becker & Pearson, 2002). A volume 
of 0.1 litre to 1 litre in the stomach after a meal would on average result in a 
DHA level of 3 to 30 mM. As a comparison, consumption of 100 g rainbow 
trout corresponds to four capsules of some Omega-3 supplements, half the 
daily dose which was recommended by the manufacturer, i.e. 6 mmol 
DHA/EPA. 
2.3.4  Influence of fat, fatty acids and surfactants on absorption of substances  
Fat-rich meals have been shown to increase absorption of certain drugs used in 
human and veterinary medicine. Several anthelmintic substances are poorly 
absorbed by the oral route, which is an advantage for the treatment, as the 
parasites exist in the GI tract lumen. When ivermectin was taken together with 
a fatty meal (48.6 g), a 2.5-fold increased bioavailability was shown in humans 
(Guzzo et al., 2002). Increased bioavailability of triclabendazole was observed 
when patients received a high energy breakfast (Lecaillon et al., 1998). The 
bioavailability of albendazole increased 4.25-fold after a fatty meal,  compared 
to when given in a fasted state (Lange et al., 1988). Furthermore, the effect of a 33 
“local fatty breakfast” on the bioavailability of albendazole was examined in a 
cross over design, which showed that the bioavailability of albendazole 
sulphoxide was increased four-fold when it was given with a fatty meal 
compared to the fasting state (Awadzi et al., 1994).  
Ivermectin is a known inhibitor of P-gp and recently it was shown to be an 
inhibitor of BCRP as well (de Vries et al., 2007; Matsson et al., 2007). The 
benzimidazoles, triclabendazole and triclabendazole sulfoxide, are substrates 
for P-gp, whereas albendazole and albendazole sulfoxide is substrates for 
BCRP (Dupuy et al., 2010; Merino et al., 2009; Merino et al., 2005a).  
Several studies have shown that surfactants interact with the function of 
efflux proteins and thereby increase absorption of certain substrates for BCRP 
(Hirunpanich & Sato, 2009; Wempe et al., 2009; Zhang et al., 2008; 
Constantinides & Wasan, 2007; Yamagata et al., 2007b; Bogman et al., 2005). 
As mentioned before attempts have been made in pharmaceutical research and 
academia to increase oral bioavailability of poorly absorbed drugs (Oostendorp 
et al., 2009; Robey et al., 2009; Anderberg et al., 1993). Medium-chain fatty 
acids (C8 to C12) have induced a dose-dependent increase of absorption of the 
paracellular marker mannitol across Caco-2 cell monolayers (Chao et al., 1999; 
Lindmark et al., 1998a). It was also found that sodium caprate (C10) induced 
leakier TJs as measured by trans-epithelial electrical resistance (TEER) 
(Lindmark et al., 1998b). Moreover, C12-fatty acids were the most effective 
absorption enhancers among the medium-chained fatty acids (Cano-Cebrian et 
al., 2005). Oleic acid (C18) was shown in Caco-2 cell monolayers to increase 
iron uptake and also to increase absorption of Lucifer yellow, a fluorophore 
which is a marker for paracellular absorption, (Droke et al., 2003). 
The surface active properties of fatty acids imply that they can be compared 
with surface active substances used as absorption enhancers in the 
pharmaceutical industry. In conclusion, the impact of fatty acids on BCRP 
efflux or other transporter protein efflux has not been investigated thouroughly.  
2.4   Possible mechanisms of fatty acids on intestinal absorption 
Paracellular absorption 
Fatty acids may affect the integrity of TJs by several ways and thereby increase 
the paracellular absorption. 
Calcium ions are important for the function of TJs as these are disrupted if 
the extracellular or intracellular concentration of Ca
2+ is reduced (Ma et al., 
2000). Complex-binding of Ca
2+ by fatty acids might reduce the amount of 
Ca
2+ available for normal function of TJ. This would result in a leakier TJ that 
allow larger molecules to pass. Fatty acids may also bind Ca
2+ and thereby 34 
cause the formation of biologically inert soaps which reduce the amount of 
Ca
2+ available for normal function of TJs (Anderberg et al., 1993). The 
intracellular presence of Ca
2+ is also important for the formation of TJs and for 
the opening of TJs (Hayashi & Tomita, 2007; Collares-Buzato et al., 1994). In 
addition, some cat-ionic substances like Cd
2+ may compete with Ca
2+ and in 
that way disrupt the TJs. 
Other possible mechanisms can include the importance of acidity (pH) for 
the integrity of the cell membrane. The pH partitioning theory means that a 
phospholipid bilayer only can be permeated by an uncharged molecule. 
However, it has later been shown that charged molecules can be absorbed 
through the paracellular route (Nagahara et al., 2004). In in vitro studies it is 
important to control the acidity in the experimental medium as an acidity 
below pH 5 or above pH 8 will damage the cell membranes (Nagahara et al., 
2004). 
Fatty acids may, like other surface active substances, penetrate the cell 
membrane, destabilize the membrane and alter the structure of it, resulting in 
an increased absorption. When the structure of the cell membrane is impaired it 
will disturb the cell-cell contacts and thereby influence the integrity of the TJs. 
This effect seems to be stronger the longer the carbon chain is and the more 
double bonds the fatty acid possesses, i.e. Traube’s law, see 2.3.1 above. 
One mechanism could be that fatty acids increase the lipophilicity of a 
substance and therefore it is easier for the substance to diffuse through the 
mucus layer and UWL and reach the enterocytes. This can be tested by 
octanol/water partitioning experiments, see Cd experiments below.  
TJs consist of pores with different sizes. Fatty acids have been shown to 
increase the number of functional pores, both large and small (Watson et al., 
2001). It is also possible that fatty acids increase the radius of the pores, thus 
letting larger molecules pass and increase the absorption in that way.  
Active transcellular absorption 
BCRP and other efflux transporters are situated in the apical membrane of the 
intestinal cells and Caco-2 cells. If a substance functions as inhibitor of BCRP 
the intestinal absorption of a substrate for BCRP increases. Thus, the efflux 
mediated by BRP will be reduced. Possible mechanisms by which surfactants 
inhibit BCRP are not known. Nevertheless, there are some mechanisms that 
might be possible.  
To work properly, active efflux requires energy. It could be speculated that 
fatty acids cause an inhibition of ATP hydrolysis, by inhibiting ATPase 
activity and in that way decreases efflux of the BCRP substrate. It has been 
shown that the surfactant Pluronic P85 inhibited, in a dose-dependent manner, 35 
ATPase activity in suspensions of P-gp overexpressing membranes (Batrakova 
et al., 2004). 
Fatty acids may act as substrates or inhibitors of BCRP. Butyrate, a short 
chained (C4) fatty acids was shown to be a substrate for BCRP (Goncalves et 
al., 2011). It could be hypothesized that simultaneous exposure of fatty acids 
and BCRP substrates or inhibitors will give a competitive inhibition of BCRP. 
It could also possible that the efflux transporter can be saturated and in that 
way reduce the efflux function.  
Another mechanism could be that fatty acids are incorporated in the cell 
membrane and are able to modulate the activity of efflux transporters, by 
altering the membrane function around the transporter (Aye et al., 2009). It has 
been shown that P-gp is partly localized to lipid rafts and that the cholesterol 
and lipid composition of the cell membrane is essential for the function o P-gp 
(Troost et al., 2004). BCRP was also demonstrated to be mainly situated in 
lipid rafts in the cell membrane and that cholesterol may considerably alter the 
efflux activity of BCRP in vitro in an MDCKII (canine kidney) epithelial cell-
line (Storch et al., 2007).  
Structure specificity is also an important factor for inhibition of transporters 
by surfactants. Only Tween 20 of the polysorbate family of surfactants was 
shown to increase MXR accumulation in MDCK-II cells (Yamagata et al., 
2007a). 
The impact of fatty acids on the PPAR-α and –γ, which in turn up-regulates 
the expression of BCRP seems to be important for the function of BCRP and 
probably other efflux transporters (Montagner et al., 2011; Hirai et al., 2007).  
2.5 Tested  Substances 
Three substances were selected for investigations of the influence of fatty acids 
on the absorption through the paracellular pathway, i.e. cadmium (Cd) (paper 
I), mannitol (papers I and II) and aluminium (Al) (paper II). MXR was chosen 
as a model substance in the studies of the effect of oleic acid on BCRP-
mediated efflux (papers III and IV). 
2.5.1 Cadmium  (Cd) 
Cd is a divalent cation but it is often found in complexes with other substances 
in food e.g. chloride (Cl
-). The main source of Cd exposure is through food, i.e. 
approximately 90% for non-smoking humans (Bergeron & Jumarie, 2006). In a 
survey of drinking water and foods in Europe, drinking water normally 
contained the lowest amount of Cd (0.001 g/kg) while horse kidney contained 
the highest amount of Cd (61 mg/kg) (EFSA, 2012). It was found that the 5
th 36 
percentile intake was 2.1 g Cd/kg bw weekly and the 95
th percentile intake 
was 12.1 g Cd/kg bw weekly (EFSA, 2012).  
Long term human exposure to low doses of Cd results in an accumulation 
of Cd in the proximal tubules in the kidney, which might result in irreversible 
renal failure. In addition, an increased risk of cancer has been indicated. Cd 
also accumulates in bones. The half-life for Cd excretion is 10 to 30 years. The 
reference point for establishing a tolerable weekly intake (TWI) was 1g Cd/g 
creatinine in urine. In order not to exceed this reference point the average daily 
dietary Cd intake should be below 0.36 g/kg bw, which results in a TWI of 
2.5 g/kg bw, as established by EFSA in 2009 (CONTAM, 2011).  
Cd might be absorbed through the GI tract either by the passive paracellular 
route, the passive transcellular route or the active transcellular route (Endo et 
al., 2000; Blais et al., 1999; Jumarie et al., 1999). Absorption of Cd is known 
to be regulated by transporter proteins, e.g. the divalent metal transporter 1 
(DMT1, SLC11A2) (Elisma & Jumarie, 2001; Tallkvist et al., 2001), ZIP8 and 
ZIP14 (Fujishiro et al., 2012; Vesey, 2010; Elisma & Jumarie, 2001; Tallkvist 
et al., 2001). DMT1 is present in the apical membrane of Caco-2 cell 
monolayers (Elisma & Jumarie, 2001; Tallkvist et al., 2001). Cd is also bound 
with high affinity to the intracellular metal-binding protein metallothionein 
(MT), and is regarded as the most potent inducer of this protein in many 
tissues, e.g. enterocytes, liver and kidney (Tallkvist et al., 2001; Rossi et al., 
1996). A dose-dependent increase in P-gp expression was shown in Caco-2 
cells after 4 weeks exposure to 1 and 5 µM Cd indicating that Cd influences   
P-gp expression (Huynh-Delerme et al., 2005). Cd ions compete with Ca
2+ ions 
which normally regulate the formation and sealing of TJs (Rossi et al., 1996). 
Recently, it was shown that CdCl2 inhibit the efflux function of MXR and 
therefore had an inhibitory effect of the function of BCRP (Kummu et al., 
2012). However, the picture of transporter proteins involved in Cd absorption 
is far greater than described here. 
Cd is known to be poorly absorbed through the intestinal epithelium. It was 
earlier estimated that only a fraction of 3 to 7% of the Cd found in food was 
absorbed in humans and only 0.3 to 3.5% in adult rats (Vesey, 2010). An 
average absorption of 5% was taken into account when EFSA established a 
TWI for Cd in 2009 (EFSA, 2009). However, diet composition and nutritional 
status has a great impact on intestinal Cd uptake. It was reported that a high 
dietary concentration of lipid and protein increased the net intestinal uptake of 
Cd (Andersen et al., 2004). 37 
2.5.2 Mannitol 
Mannitol (mw 182.17) is a sugar alcohol, derived from reduction of sugar, 
(C6H8(OH)6). It is for example used in medicine as an osmotic diuretic and also 
for reducing intracranial pressure. It is also used as a food additive (E421) and 
sweetener, where the poor absorption is beneficial for its use. Mannitol is 
exclusively absorbed through the TJs, i.e. the paracellular pathway, and is 
therefore commonly used as a marker for the paracellular absorption (Hubatsch 
et al., 2007; Anderberg et al., 1993).  
2.5.3 Aluminium   
Aluminium (Al) is naturally present in food in low concentrations (µg/kg), in 
tea, cocoa, herbs, spices and drinking water (Yokel et al., 2008; Jorhem & 
Haegglund, 1992). However, food can also be contaminated during processing, 
cooking and storage, thereby resulting in a rather high intake for consumers, 
i.e. 90 mg Al/week in Sweden (Jorhem & Haegglund, 1992). Al is also 
included in food additives (e.g. anticaking powder) and in drugs (e.g. vaccines, 
antacids), both for human and veterinary use (Crisponi et al., 2012; Greger & 
Sutherland, 1997). A tolerable weekly intake of 1 mg Al/kg bw has been 
established by both EFSA (EFSA Panel on food additives, 2008) and JECFA 
(JECFA, 2006). The TWI was based on the no-observed-adverse-effect level 
(NOAELs) in mammals for neurotoxicity, embryotoxicity and testicular 
toxicity.  
Al is generally insoluble at neutral pH but can be solubilised by complexing 
agents, such as citrate, lactate, fluoride and silicate present in food (Zhou & 
Yokel, 2005; Glynn et al., 2001; Froment et al., 1989; Slanina et al., 1986). Al 
has, in some studies, been shown to be absorbed by the paracellular route 
(Aspenstrom-Fagerlund et al., 2009; Zhou & Yokel, 2005; Whitehead et al., 
1997; Provan & Yokel, 1988). Recently an influx transporter, Nrat1 (a member 
of the Nramp family of transporters) was found to function as an Al influx 
transporter in rice, specified for trivalent ions (Xia et al., 2011). However, no 
information of other transporters for aluminium was found. 
Certain diseases or physical conditions might modify toxicokinetics of Al 
and thereby increase its absorption and bone deposition (Crisponi et al., 2012). 
The risk assessment assumes a low absorptive bioavailability of Al, which is 
less than 1% in laboratory animals and humans (Yokel & McNamara, 2001; 
Greger & Sutherland, 1997). In the risk assessment of Al, the impact of food 
on the bioavailability has not been taken into account.  38 
2.5.4 Mitoxantrone 
 
Figure 9. Mitoxantrone (MXR), 1,4-dihydroxy-5,8-bis[2-(2-hydroxyethylamino) ethyl amino]-
anthracene-9,10-dione, C22H28N4O6 , Mw 444.48 
MXR is an anthracenedione, antineoplastic agent used for example in the 
treatment of breast cancer, acute leukemia’s and non-Hodgkin’s lymphoma in 
humans and animals since the 1980
th (Batra et al., 1986). MXR is genotoxic 
and acts as a topoisomerase II inhibitor, disrupting DNA synthesis and DNA 
repair in both healthy cells and cancer cells (Boos & Stopper, 2000; Stopper et 
al., 1999). As a therapeutic agent MXR is administered by the parenteral route, 
since absorption by the oral route is not efficient enough (Scott & Figgitt, 
2004; IARC, 2000; Batra et al., 1986). The low oral bioavailability is due to 
the presence of BCRP in the intestine (Matsson et al., 2009; Doyle & Ross, 
2003). Thus, MXR is often used as a model substance to study BCRP-mediated 
efflux of substances (Matsson et al., 2007; Yamagata et al., 2007a; Yamagata 
et al., 2007b; Cisternino et al., 2004).  
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3  Aims of the thesis 
The overall aim was to examine whether dietary fat increase absorption of food 
toxicants by modifying the barrier functions of the intestinal epithelium. The 
impact of food components, like fatty acids, on absorption of toxic substances 
is currently not taken into consideration in risk assessment.  
The specific aims were: 
1.  To investigate in vitro if fatty acids common in food, i.e. oleic acid and 
DHA, compromise the integrity of the intestinal epithelium causing 
increased paracellular absorption of poorly absorbed hydrophilic 
substances such as mannitol, cadmium and aluminium (Papers I and II). 
 
2.  To investigate in vitro and in vivo, if oleic acid negatively affects the 
function of the efflux transporter BCRP by investigating the absorption 
of the BCRP substrate MXR and to investigate the influence on gene 
expression of BCRP (Papers III and IV). 40 
4  Materials and methods 
An overview of the methods used in this thesis is given in this section. Details 
and the full description of the experiments are given in the individual papers 
included as papers I to IV.  
4.1 Experimental  models 
The effect of fatty acids, commonly present in food, on transport of poorly 
absorbed toxic substances either by the passive paracellular pathway or the 
active transcellular pathway was investigated both in vitro and in vivo. Caco-2 
cell monolayers were used in the in vitro investigations and FVB male mice in 
the in vivo investigations. 
4.1.1  Human intestinal epithelial enterocytes, Caco-2 cell  
monolayers (Papers I, II, III) 
The Caco-2 cell model is an experimental model of human absorptive 
enterocytes. Caco-2 cells are derived from a human primary colorectal adeno-
carcinoma from a 72 year old patient (Fogh et al., 1977). Caco-2 cells are 
widely used for studies of absorption of drugs, nutrients and toxic substances, 
both in the academia and in the pharmaceutical industry.  Searching Pubmed, 
using the search term “Caco-2” gives more than 10 000 hits (July 2012). When 
fully matured, the Caco-2 cells are polarized into an epithelial cell monolayer 
that provides a physical and biochemical barrier to the passage of ions and 
molecules. The reason why cancer cells are used is because they can be grown 
for longer time than normal cells which only survives for approximately 10 
days when cultivated.  
When Caco-2 cells are seeded on permeable filters and placed in bicameral 
chambers, they differentiate spontaneously, polarize and form monolayers. 
During the differentiation phase the monolayers develops a phenotype similar 41 
to the small intestinal absorptive enterocytes with a well-differentiated brush 
border (Artursson et al., 2001; Pinto, 1983). The monolayers with its brush 
border express typical small intestinal microvilli hydrolases, enzyme systems, 
transporters for absorption and efflux, as well as tight junctions with typical 
tight junctional proteins (Englund et al., 2006; Delie & Rubas, 1997; Meunier 
et al., 1995). The correlation of gene expression of ten efflux proteins was 
compared between the human jejunum and Caco-2 cell monolayers 
(Taipalensuu et al., 2001). A good correspondence between Caco-2 cells and 
human jejunum for 9 of 10 transporter proteins (including P-gp) was found. 
However, less agreement was found for BCRP which had a 100-fold lower 
transcript copy number in Caco-2 cells compared to human jejunum.  Both the 
monomer and dimer of BCRP are expressed in fully differentiated Caco-2 cells 
and situated at the apical side of polarized Caco-2 cells (Ebert et al., 2007; 
Yamagata et al., 2007b; Xia et al., 2005). 
The monolayers do not produce mucus, which means that apical exposure 
to substances will take place without this protecting layer in Caco-2 cell 
experiments. Independent measures of test substances on the apical side 
(directed towards the intestinal lumen) and the baso-lateral side (directed 
towards the blood) of the monolayer can easily be carried out.  
Culturing and differentiation of Caco-2 cells 
The Caco-2 cells were a kind gift from Professor Artursson, Department of 
Pharmacy, Uppsala University.  Cells were grown mainly according to the 
protocol for culturing of Caco-2 cells designed by that group (Hubatsch et al., 
2007). In the current experiments Caco-2 cells were first grown to reach 
confluency in plastic flasks (25 and 75 cm
2) in a cell incubator under 
standardized conditions. At confluence, which takes two to three days, cells 
were detached with trypsin and split at a 1:2 ratio into two new flasks or seeded 
on filters. A passage means the number of times that cells have been sub-
cultured into a new flask. In our experiments a rather high passage, 92 to 97, 
was used. In some early experiments we used passage 50 to 100. Cells were 
seeded on Falcon filters in six-well plates, and with a cell density of 1.5 to 2.0 
x 10
6 cells per filter. The culture medium was changed both apically and 
basolaterally every second or third day. The step of growing on the filters is 
called the differentiation phase and it takes 20 to 25 days to get fully 
differentiated monolayers with the characteristics of the small intestinal 
epithelium. If cells grow too long they start forming multilayers and are then 
not suitable to use in transport experiments.  
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Figure 10. This figure shows a six well plate with six filter inserts and the cells with the brush 
border. (P Aspenström). 
4.1.2  FVB male mice (Paper IV) 
The influence of oleic acid on the absorption of MXR was tested in FVB male 
mice. BCRP is expressed in organs important for absorption (small intestine, 
colon), distribution (the blood-brain and placental-barriers) and elimination 
(canalicular membranes of hepatocytes) and also in kidney in mice. BCRP was 
shown to be expressed in the intestine of FVB mice (Enokizono et al., 2007b; 
Jonker et al., 2000). The highest amount of BCRP/villus was found in the 
ileum followed by jejunum, duodenum and colon (Han & Sugiyama, 2006; 
Tanaka et al., 2005). The FVB mice have been used to study BCRP efflux of 
topotecan, a typical BCRP substrate (Yamagata et al., 2007b). Furthermore, 
oral absorption of the BCRP substrates aflatoxin B1 and heterocyclic amines 
(IQ and Trp-P-1) was increased when given to a mice strain devoid of BCRP 
(BCRP
-/- FVB male) compared to FVB Wt (Wild type) male mice (van 
Herwaarden et al., 2006). Thus, the FVB mice strain has been shown to be a 
good model for studies of oral absorption of BCRP substrates. The amount of 
BCRP was slightly higher in male mice and therefore it seemed reasonable to 
choose male mice in the studies. 
FVB Mice (NCrl, male, 8 weeks) were randomly assigned to different cages 
and acclimatized in a temperature- and humidity-controlled room with a 12 h 
light/dark cycle for one week before experiments were initiated. Tap water and 
standard diet were given free. The standard diet for the mice comprised of 7.43 
E% fat and 0.88 w/w % MUFA and 0.88 w/w % PUFA. Mice were fasted over 
night with free access to water before the experiments.  
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4.2 Experimental  procedure 
4.2.1  In vitro absorption and accumulation experiments (papers I-III) 
Absorption and accumulation experiments were performed at 37ºC in a cell 
incubator with continuous shaking (rpm 33), in order to minimize the influence 
of the aqueous boundary layer on the cell surface, which otherwise can 
influence permeability of substances (Artursson et al., 1993).  
Fatty acid emulsions of protonated fatty acids were prepared in 
experimental medium by sonification in Labsonic 1510 (B. Braun), maximum 
400 W for 2 x 20 seconds, directly before addition of radiolabelled substances 
and before test emulsions were added to the cell monolayers. The fatty acid 
concentration of the test emulsions was not measured after sonification, but it 
was assumed that there was no loss of added fatty acid in the test emulsions. 
The pH of all emulsions was measured before added to the monolayers. The 
experiments were performed in six well plates and exposure was only carried 
out from the apical to the basolateral side of the monolayers. In all experiments 
the test solutions, with or without fatty acids, were added to the apical donor 
side and pure experimental medium was added to the basolateral receiver side 
of the Caco-2 cell monolayers. 
As indicators of cell toxicity lactate dehydrogenase (LDH) and protein 
content in wells were measured in all cell studies. Cell integrity was 
determined by measuring transepithelial electrical resistance (TEER).   
Paper I:  
In experiment I, the influence of fatty acids, with or without Ca
2+ in the test 
emulsion, on absorption of mannitol across Caco-2 cells were investigated. 
Emulsions of oleic acid (5, 15 or 30 mM) or DHA (5, 15 or 30 mM) were 
tested. To each well in the control groups and fatty acid exposed groups 
14C-
mannitol was added in a concentration of 16 mannitol corresponding to 2 
µCi/well. The test emulsions were added to the apical side of the monolayers 
(n=5-6 for each group) and samples were collected both basically and apically 
at different time points. Morphology of monolayers was analyzed with 
fluorescence microscopy, as described below, 4.3.4.  
In experiment II, Caco-2 cell monolayers were exposed to Cd solutions 
(250 nM), with 
109Cd (1.5 mCi/well) as a tracer, in test emulsions of oleic acid 
(5 and 30 mM) or DHA (1 and 5 mM). Control groups were exposed to the Cd 
solution in experimental medium. Samples were collected at different 
timepoints and accumulation of Cd within cells was analyzed as described 
below, 4.3.3. The lipophilicity of Cd in oleic acid and DHA emulsions was 
measured as the octanol/water partition coefficient as described in 4.3.5. 44 
Paper II: 
The influence of fatty acids (DHA and oleic acid) on mannitol and Al 
absorption across Caco-2 cell monolayers, from the apical to the basolateral 
side, was investigated. To begin with, in order to find a concentration of Al that 
was not toxic to the cells, a dose-finding study was performed. Absorption of 
Al and 
14C-mannitol across Caco-2 monolayers was measured at different 
concentrations of Al (0, 1, 2, 4, 10, 20 and 30 mM) during 90 min.  
Secondly, monolayers were exposed to 
14C-mannitol (2 µCi/well, 
corresponding to 16 mannitol) in emulsions of oleic acid (15 and 30 mM) 
or DHA (5 and 10 mM) and 2 mM Al. Samples for analyses of 
14C-mannitol 
and Al were collected after 90 min both from the apical and basolateral side of 
the monolayers. The morphology of cell monolayers were analysed with 
transmission electron microscopy (TEM), as described below, 4.3.4. 
Paper III:  
The influence of oleic acid on MXR absorption, restricted by BCRP, was 
investigated in vitro in the Caco-2 cell monolayer model.  
Before the fatty acid experiments, cytotoxicity and apical to basolateral 
absorption of MXR were tested at different concentrations of MXR (0.1, 1, 10, 
50, 100, 500 and 1000 µM MXR). Then, the effect of oleic acid (0.5, 1, 2, 4 
and 5 mM) on the absorption of MXR (1 µM) across the cell monolayers was 
investigated. Radiolabelled 
3H-MXR (~200 000 cpm/well corresponding to 0.1 
µCi) was used as a tracer. The influence of the BCRP substrate cimetidine (0.1 
mM) and the BCRP inhibitor Ko143 (1µM) on MXR absorption over the 
monolayers was also tested. Moreover, the influence of oleic acid on the 
absorption of MXR after preincubation with oleic acid in culture medium 
(DMEM) for 5.5 h was tested. The incubation period was followed by a 
stepwise removal of oleic acid before MXR exposure. Quantitative gene 
expression of BCRP was measured by qRT-PCR and the amount of BCRP was 
measured with Western Blot after exposure to oleic acid during 3, 6, 9, 24 
hours, as described below, section 4.3.6.  
4.2.2  In vivo, absorption experiments (paper IV) 
Paper IV: 
Firstly, the influence of oleic acid on the absorption of MXR in vivo in mice 
was investigated.  
A time-dependency study was carried out. Mice were dosed by gavage with 
an oleic acid emulsion (2.4 g/kg bw) with 1 mg MXR/kg bw and radiolabelled 
3H-MXR as a tracer. The dose was divided by three and given in 30 min 45 
intervals during 1 h. The mice were sacrificed after 30, 60, 90 and 120 min 
post-dosing in groups of 5 to 6 individuals. Each oleic acid-treated group 
(sacrificed at different time points) had its own control group treated with 
MXR solution devoid of oleic acid.  
Secondly, a dose dependency study was carried out, where mice were 
treated with emulsions of 0.6, 2.4 or 4.8 g /kg bw oleic acid and 1 mg/kg bw 
MXR /mouse. The dose were divided by three and given in 30 min intervals, as 
in the previous study. At 90 min post-dose the mice were sacrificed randomly.  
In both experiments, mice were anaesthetized with isoflurane and sacrificed 
by heart puncture during blood sampling. Tissue samples from the liver, 
kidney, brain and intestine were removed and put in vials for dissolution, 
bleaching and scintillation counting as described below (4.3.2). Gene 
expression of BCRP was measured in the samples from jejunum, kept in RNA 
later, in the time-dependency experiment as described below (4.3.6). 
4.3 Experimental  techniques 
Most experiments were carried out at the National Food Agency, Uppsala. 
Morphology studies with fluorescence microscopy were done at the Ludwig 
Institute for Cancer Research, Uppsala. Morphology studies with transmission 
electron microscopy, as well as gene- and protein-expression studies, were 
performed at the Department of Biomedical Sciences and Veterinary Public 
Health, Swedish University of Agricultural Sciences, Uppsala, Sweden.  
4.3.1 Cell  integrity (papers I-III) 
Trans-epithelial electrical resistance (TEER) 
TEER is an indicator of epithelial integrity measuring ion flow through the cell 
monolayers. Electrical conductivity is mainly limited to the paracellular ion 
flux in Caco-2 cell monolayers, and therefore serves as a good marker for 
epithelial integrity, i.e. the tightness of TJs. Leaky TJs results in a lower TEER 
than in tight TJs. TEER was measured in an EndOhm 24 Snap chamber using 
an epithelial volthometer (EVOM24 mm, World Precision Instruments, WPI 
Inc. Stevenage, UK). TEER was measured as Ω x cm
2, and was typically 200 
to 300 Ω x cm
2. The TEER value from an empty well was subtracted from the 
TEER value. TEER was expressed as  
(TEER after preincubation with pure experimental medium/TEER at the end of exposure) x 100 
4.3.2  Cytotoxicity (papers I-III) 
Cytotoxicity was measured as lactate dehydrogenase (LDH) leakage and 
protein content in the wells.  46 
Lactate dehydrogenase leakage (LDH) 
LDH is an intracellular enzyme present in most cells. If LDH is found in the 
cell medium it is an indication of that there is a cell leakage caused by a 
damaged cell membrane or lysis of the cells. LDH was measured using a 
cytotoxicity kit from Roche with a Caco-2 cell monolayer treated with 2% 
Triton X-100 as an indicator for maximal cell leakage of LDH. The samples 
were analyzed with spectrophotometry. LDH leakage for a sample was 
expressed as  
(LDH leakage from exposed monolayers/LDH leakage from TritonX- treated monolayers) x 100. 
Protein content in wells 
Protein content in wells is a marker of cell detachment from filters and of an 
increased leakage of intracellular proteins from the cells. An increase in protein 
content could hypothetically be due to an induction of protein synthesis. A low 
content of protein in the wells shows that cells have died or that cells have 
detached from the monolayer. Cells on filters were lysed with NaOH at the end 
of the experiments and then stored in -20°C before analyses. Protein analyses 
was performed with a photometrical method according to Hartree (Hartree, 
1972) in paper I or a colorimetric assay kit (DC protein assay (BioRad, Life 
Science Research, Hercules, USA) in paper II, III. 
4.3.3  Preparation and analysis of tested substances (papers I-IV) 
Mannitol (paper I-II) 
Radiolabelled 
14C-mannitol was analyzed in a -scintillation counter (Wallac 
1409, LKB Wallac, Finland). Scintillation liquid (Quicksafe A, Zinsser 
Analytic) was added to the samples that were equilibrated over night before 
scintillation counting. The apical to basolateral passage of 
14C-mannitol 
through monolayers was calculated as the percentage of the amount added at 
the apical side retrieved on the basolateral side at different timepoints or at the 
end of treatment. 
Cadmium absorption over the monolayers and cadmium accumulation inside 
cells (paper I) 
Radiolabelled Cd (
109Cd) was added to unlabeled Cd to a final concentration of 
250 nM Cd (1.5 mCi/well). Radiolabelled 
109Cd was analyzed in a gamma 
counter (Nuclear Chicago, Model 1185, with a counting efficiency of 37%). 
Absorption of Cd was calculated as per mille of Cd that had passed across the 
monolayers from the apical to the basolateral side.  47 
Accumulation of 
109Cd within cells was measured at the end of the 
experiments. Cells were washed on the apical side with EDTA twice to remove 
surface-bound Cd and thereafter cells were lysed with NaOH.
 Accumulation of 
Cd in the cells at the end of the experiment was calculated as the amount of 
109Cd in the cells (pmol Cd/mg protein for each monolayer). 
Aluminium 
The Al solution was prepared by mixing 100 mM Al chloride (AlCl3*6H2O) in 
experimental medium with 200 mM tri-sodium-citrate. Al was analysed using a 
Perkin-Elmer Analyst-600 atomic absorption spectrometer (Perkin-Elmer, 
Norwalk, Connecticut, USA) equipped with Zeeman background correction, 
transversely heated graphite furnace and an auto sampler AS-800. The limit of 
detection (LOD) determined for this method is 2 µg/l. Apical to basolateral 
absorption of Al across the cell monolayers was calculated as fractional 
absorption, i.e. the % of apical Al retrieved at the basolateral side of the 
monolayers.  
MXR  
In vitro studies: A stock solution of MXR in HBSS was prepared. 
Experimental solutions were prepared by dilution of the stock solution. 
Radiolabelled 
3H-MXR, was added as a tracer to the unlabelled solutions just 
before experiments, in order to get the final solutions for the oleic acid 
experiments of 1 µM MXR and for the dose-response experiment of 0.1, 1, 10, 
50, 100, 500 and 1000 µM MXR. Radiolabelled 
3H-MXR were measured in 
the scintillation counter (Wallac 1409, LKBWallac, Finland). Scintillation 
liquid (Quicksafe A, Zinsser Analytic) was added to the samples that were 
equilibrated over night before scintillation counting. Apical to basolateral 
absorption of MXR across the cell monolayers was calculated as fractional 
absorption, i.e. the % of apical 
3H-MXR retrieved at the basolateral side of the 
cell monolayers.  
Accumulation of 
3H-MXR within cells was measured at the end of the 
experiments. Cells were washed to remove surface-bound MXR as described 
for Cd accumulation above and thereafter the cells were lysed with NaOH.
 
Scintillation liquid was added to sample vials as described previously. 
Accumulation of MXR in the cells was measured at the end of the experiment 
as pmol MXR/mg protein for each monolayer.   
In vivo studies: A stock solution of MXR in HBSS was prepared. Each 
mouse was dosed with 1 mg MXR/kg bw as well as 1µCi 
3H-MXR to each 
mouse, as a tracer. Blood was sampled in heparinized tubes and plasma was 
separated by centrifugation. Samples from plasma, liver, kidney, brain and 48 
intestine were dissolved and bleached for scintillation. Scintillation liquid was 
added to the samples and they were measured as described above. Results were 
expressed as cpm/g tissue or cpm/ml plasma. The ratios between tissues and 
plasma were calculated. 
4.3.4  Morphological examination (papers I and II) 
Fluorescence microscopy (paper I) 
Morphology of cell monolayers was studied with fluorescence microscopy. 
The -catenin was stained in cell-cell contacts and visualized. Cell monolayers 
on filters were fixed in para-formaldehyde in PBS, followed by 
permeabilisation with Triton-X and incubation with fetal bovine serum. The 
filters containing the cells were removed from the cell culture inserts with a 
scalpel and then incubated with a mouse monoclonal anti -catenin antibody, 
followed by a tetramethyl rhodamine isothiocyanate (TRITC)-conjugated anti-
mouse antibody, with a washing step between. The membranes were mounted 
on object slides using Fluoromount-G, and covered by a coverslip. Confocal 
analysis was performed on a Zeiss Axiovert 200 M equipped with a LSM 510 
laser.  
Transmission electron microscopy (paper II) 
The morphology of cell monolayers was studied by using transmission electron 
microscopy (TEM). Monolayers were fixed in sodium phosphate buffer (SPB) 
containing glutaraldehyde, followed by fixation in SPB, containing 1% 
osmium tetra oxide and then finally embedded in Agar 100 resin (Agar 
Scientific, UK). The embedded cells were sectioned and stained with uranyl 
acetate and lead citrate (Lindmark et al., 1998b). Sections were analyzed in a 
Philips 420 electron microscope operated at 60 kV. The magnification was 
11000 times.   
4.3.5 Octanol/water  partition coefficients (paper I) 
The octanol/water partitioning coefficient (P) is an indicator of the lipophilic 
nature of a substance. Octanol is assumed to have the lipophilicity comparable 
to a cell membrane and P describes the ability of a substance to partition in the 
lipophilic phase (Artursson et al., 2001). The pH 7.4 was used in our 
experiments as it is the physiological pH of the interstitial fluid in microvilli of 
the small intestine. P of Cd (250 nM 
109Cd-solution) was tested at different 
concentrations of oleic acid (5 and 30 mM) and DHA (1 and 5 mM) according 
to the OECD Guidelines, test 107, with some modifications (OECD).  The 
samples were measured in a gamma-counter and P was calculated as P = cpm 
(octanol)/cpm (Cd emulsion). The results were presented as logP. 49 
4.3.6  Gene expression (papers III and IV) 
Gene expression of BCRP was analysed in Caco-2 cells and in the intestine 
from mice exposed to oleic acid. Caco-2 cell monolayers (n=3) were exposed 
to oleic acid at different time-points. Each time-point had its own controls 
(n=3). In addition, samples from intestine (jejunum) from oleic acid exposed 
mice were analysed. Total RNA was isolated by using a Nucleospin
®RNAII kit 
from Macherey-Nagel (Germany) according to the manufacturer’s instructions. 
The integrity of the isolated RNA was confirmed by ethidium-bromide agarose 
gel electrophoresis. Quantification of the RNA was performed according to the 
RNA-specific RiboGreen protocol with Dnase I (In vitrogen, Stockholm, 
Sweden).  
BCRP gene expression was measured by real-time RT-PCR, using the 
QuantiTect RT-PCR kit with SYBR Green (Qiagen®, Inc, Valencia, CA, 
USA) according to the instructions by the manufacturer and the primers in 
table 3. RT-PCR reactions were performed by the use of a Rotor-Gene, RG 
3000 instrument (Corbett Research, Mortlake, Australia) in the presence of 200 
ng templates RNA. Melt curve analyses were performed for each sample in 
direct connection to the RT-PCR. For studies of the specificity of the obtained 
PCR products Rotor Gene software was applied. 
Table 3. Primer sequences used for quantitative real-time PCR 
Primer Oligo  sequence 
BCRP forward  5´-GCT TAG ACT CAA GCA CAG CAA A-3´ 
BCRP reverse 
mBCRP forward 
mBCRP reverse 
5´-GGC CCG TGG AAC ATA AGT C-3´ 
5´-CGC AGA AGG AGA TGT GTT GA-3´ 
5´- TTG GAT CTT TCC TGG CTG CT-3´ 
In the cell experiments the relative quantification of BCRP gene expression 
was calculated. Calculated values describe the change in expression of the 
target gene in the exposed groups in relation to the expression in the untreated 
controls using the 2
-(ΔCt) method (Schmittgen & Livak, 2008).  
In the in vivo experiments, BCRP was quantitatively measured. A standard 
curve for each real-time RT-PCR was prepared, and concentration of BCRP in 
each sample from the intestine was calculated from the standard curve. 
4.3.7 Protein  expression (paper III) 
Western blot analyses were done to measure the amount of BCRP in Caco-2 
cells, which were exposed for oleic acid (1mM) in culture medium for 1.5 h or 
6 h. Monolayers of Caco-2 cells only exposed to DMEM were used as controls. 50 
After exposure, cells were scraped off the filter inserts and subsequently lysed 
in hypotonic lysis buffer, sonificated and centrifuged to remove insoluble 
material. The protein content in the cell lysate was measured as described 
above (4.3.2). Protein (15 g) was unfolded by using Laemmli buffer with 
SDS and boiling, followed by separation on SDS-PAGE. After the 
electrophoresis, protein was transferred to nitrocellulose membranes (BioRAD 
laboratories). Membranes were blocked in blocking agent and then incubated 
with BCRP/ABCG2 antibodies (BXP-53, Abcam) diluted in PBST followed by 
the secondary antibodies HEP conjugated rabbit polyclonal anti-rat antibodies 
(1Ab 6374, Abcam) diluted in PBST. BCRP was detected by using enhanced 
chemi-luminescence (General Electric Healthcare). Detection and 
quantification of the intensities of the obtained 72 kD bands were done with the 
Chemi-Doc Gel Quantification System and Quantity One software (BioRad). 
The protein expression of BCRP was normalized against the protein expression 
of tubulin. 
4.4 Statistical  analysis 
The in vitro experiments were carried out using 3 to 6 cell monolayers per 
exposure group. Results were expressed as mean or median ± S.D. Differences 
between the control and exposed groups were tested using the Mann-Whitney 
U-test. Mann Whitney U-test is a two sample test, testing the hypothesis that 
the control and the exposed groups have equal medians, against the possibility 
that the two groups do not have equal medians (a two-sided test). The level of 
significance was set at 0.05. The correlations between fractional Al and 
mannitol absorption were analyzed using the nonparametric Spearman rank 
correlation test and was expressed as correlation coefficients. All statistical 
analyses were performed using Graph Pad Prism 5.00 or Minitab 15.   51 
5  Results and discussions 
This section contains the results from this thesis and a few additional results 
that have not yet been published. For the complete description of each studies 
the individual papers could be considered, paper I-IV. 
5.1  Influence of passage number on absorption of  
aluminium and mannitol 
Caco-2 cells are grown in many laboratories under different conditions such 
as various culturing techniques, seeding densities, culturing time and different 
passage numbers, resulting in quite heterogeneous cell populations (Hayeshi et 
al., 2008). Thus, the general population of Caco-2 cells consists of a 
heterogeneous mixture of cell clones. Each passage might result in a selection 
of fast growing subpopulations (Yu et al., 1997). Comparison of results from 
different laboratories may therefore be difficult. Passage numbers ranging from 
20 to over 100 have been used in different studies (Delie & Rubas, 1997).  
In an unpublished experiment, we elucidated the importance of passage 
number (50 to 100) of cultured cells on absorption of aluminium and mannitol. 
The cells at different passages were fully differentiated on filters and transport 
experiments were performed as described for Al and mannitol studies in paper 
II. The cells were exposed apically to 0, 5 or 25 mM Al-citrate and 
14C-
mannitol (unpublished data). It was found that the relative TEER (TEER 
before exposure compared with TEER at the end of exposure) increased with 
increasing passage number up to passage 100, especially in the Al-exposed 
groups. Thus, the epithelium was tighter at higher passage numbers, which 
resulted in a decreased absorption of mannitol and Al with increasing passage 
number. Mannitol absorption decreased both in control and Al exposed 
monolayers at increasing passage numbers. Similarly, it has been shown that 
passage-dependent absorption of mannitol was inversely associated with 52 
passage-dependent changes in TEER (Briske-Anderson et al., 1997; Yu et al., 
1997). However, the results indicated that the number of passages in serial 
culturing of Caco-2 cells has an impact on the sensitivity of the Caco-2 cell 
monolayers for Al. Al exposure caused a more pronounced decrease in relative 
TEER at lower passage numbers, suggesting a higher Al sensitivity at lower 
passage numbers than at higher passage numbers.  
 
Figure 11. The influence of different passage numbers (50, 60, 70, 80, 90 and 100) on the 
absorption of 
14C-mannitol and Al across fully differentiated Caco-2 cell monolayers after 60 min 
exposure to 
14C-mannitol in Al-free experimental medium, or 5 or 25 mM Al-citrate in 
experimental medium, (n=6) (mean +SD). 
a) Statistically significant in relation to passage 50 in 
each exposed group, at P<0.05 (Mann Whitney U-test). 
b) Statistically significant compared with 
each corresponding passage in the control group, P<0.05. 
c) Statistically significant compared with 
each corresponding passage in 5 mM Al-citrate at P<0.05 (Mann Whitney U-test). 
Increased growth rate, TEER and sucrose activity in Caco-2 cells were found 
as passage increased (Briske-Anderson et al., 1997). In addition, more 
homogenous cells were found at confluence at higher passages. This indicate 
that a selection process might be possible, where more robust cells have 
survived. Higher passage number was also shown to increase the possibility 
that cell monolayers grows in multiple layers causing an increased TEER 
(Briske-Anderson et al., 1997). However, we have not found multiple layers in 
our experiments. Thus, it is important to follow the same procedures from time 
to time in a laboratory and also to use the same passages to get comparable 53 
results. We concluded that it is appropriate to use high passaged cell 
monolayers to reduce the impact of toxicity on the cells, influencing 
absorption. 
5.2  Fatty acids influence tight junction permeability and 
absorption (papers I and II) 
5.2.1  Absorption of mannitol and cadmium across  Caco-2 cell monolayers is 
enhanced by DHA and oleic acid (paper I) 
The influence of fatty acids (oleic acid and DHA) on the absorption of 
mannitol and Cd in Caco-2 cell monolayers was investigated. Apical to 
basolateral absorption of mannitol across the cell monolayers increased with 
increasing concentrations of both oleic acid (15 and 30 mM) and DHA (5, 15 
and 30 mM) in the presence of Ca
2+ after 90 min exposure (figure 12 A). When 
the experimental medium was devoid of Ca
2+ the effect was approximately 7 
times higher for DHA and 3-4 times higher for oleic acid (figure 12 B). At the 
same time TEER decreased in the same manner (figure 12 C). DHA was more 
cytotoxic than oleic acid, but the effects were still dependent on the presence of 
Ca
2+ in the experimental medium.  
The results show that the presence of Ca
2+ in the experimental medium is 
important for the function of TJs in Caco-2 cell monolayers, as TEER 
decreased and cytotoxicity of fatty acids increased when experimental medium 
was devoid of Ca
2+. In presence of Ca
2+ the fatty acids had effects on tight 
junctions without causing measurable cytotoxicity (Aspenstrom-Fagerlund et 
al., 2007). It is important to keep the Ca
2+ level in medium at a physiological 
level on both sides of the cell monolayers (Anderberg et al., 1993). TJs 
between intestinal epithelial cells are dynamic and the TJ tightness can be 
modulated by intracellular and extracellular events (Delie & Rubas, 1997).  
The TJ protein -catenin is important for the function of cadherin and its 
adhesive properties. In paper I, the morphology of cell monolayers was studied 
with fluorescence microscopy. We showed that control monolayers exposed to 
experimental medium with or without Ca
2+ for 90 min had a distinct 
localization of -catenin to the cell-cell contacts and a homogenous and 
confluent cell monolayer (figures 13 A and C). 
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Figure 12. Absorption of 
14C-mannitol in Caco-2 cell monolayers exposed to emulsions of oleic 
acid (OA) or DHA in experimental medium A) with or B) without Ca
2+ and Mg
2+ for 90 min. C) 
Relative TEER in % for Caco-2 cell monolayers exposed for 90 min to oleic acid or DHA, in 
experimental medium (1) with or (2) without Ca
2+ and Mg
2+ (n=6). *)Statistically significant in 
relation to controls. P<0.05 (Mann- Whitney U-test).  
Cells exposed to 30 mM oleic acid for 90 min in experimental medium with 
Ca
2+ still showed confluent monolayers. However, an increased dissolution of 
the cell-cell contacts was seen as the localization of -catenin was not as 
distinct compared to controls (figure 13 B). Cells exposed to 5 mM DHA in 
experimental medium without Ca
2+ showed a profound alteration of cell-cell 
contacts (figure 13 D). In addition, the thickness of the cell monolayers was 
decreased. The results, visualized by fluorescence microscopy, confirmed the 
results that oleic acid and DHA even at rather low concentrations (5 mM) have 
cytotoxicity effects in  Caco-2 cell monolayers. In all further studies 
experimental medium with Ca
2+ was used as the cytotoxicity was more 
pronounced when experimental medium was devoid of Ca
2+.  
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Figure 13. The organization of cell-cell contacts was visualized by staining cells with a mouse 
anti--catenin antibody followed by TRITC- conjugated anti-mouse antibody. Control 
monolayers visualized in (A) and (C) was treated with experimental medium with and without 
Ca
2+ and Mg
2+, respectively. (B) Cell monolayers were treated with emulsion of 30 mM OA in 
presence of Ca
2+ and Mg
2+. (D) Cell monolayers were treated with 5 mM DHA in experimental 
medium devoid of Ca
2+ and Mg
2+. X, Y and Z are the co-ordinate axis that shows the cells three-
dimensionally. (Fluorescence microscopy: Photo P Aspenström) 
In paper I, it was also investigated if oleic acid and DHA influence absorption 
and accumulation of Cd, which is a poorly absorbed hydrophilic toxic 
substance. In a dose finding study, Caco-2 cell monolayers were apically 
exposed for 180 min to different concentrations of CdCl2 in experimental 
medium containing Ca
2+. It was found that a concentration of 250 nM CdCl2 
did not affect TEER or LDH leakage. In a subsequent experiment the effects of 
oleic acid and DHA on absorption of Cd from the apical to the basolateral side 
of Caco-2 cell monolayers was investigated. Absorption of Cd in emulsions of 
DHA (1 or 5 mM) increased after 120 and 180 min exposure, simultaneously 
as TEER and protein content in cell monolayers was decreased, and LDH 
leakage increased (figure 14).  
An octanol/water partitioning experiment with Cd showed that the 
lipophilicity of Cd increased in the following order:  
5 mM oleic acid < 30 mM oleic acid ≤ 1 mM DHA < 5 mM DHA 56 
Thus, the lipid solubility of Cd increased in the presence of both oleic acid and 
DHA. Exposure to Cd in emulsions of oleic acid (5 and 30 mM) for 180 min, 
did however not result in an increased absorption of Cd. TEER, LDH leakage 
and protein content in cell monolayers were either not influenced. This 
suggests that increased lipid solubility was not the reason for the higher 
absorption of Cd in presence of DHA. It therefore appears that the paracellular 
absorption of Cd is increased when cells are exposed to DHA.  However, as Cd 
is also absorbed through other pathways as the passive and active transcellular 
routes (Jumarie et al., 1999), it could not be proven in these experiments that 
the influence of DHA on Cd absorption is on the paracellular pathway.  
 
Figure 14. Absorption of Cd (‰ of apical dose), following exposure of Caco-2 cell monolayers to 
109Cd in emulsions of oleic acid or DHA during 180 min (n= 5).  
DHA was shown to increase Cd absorption at the same time as it was toxic to 
the cell monolayers and caused leakier TJs. The disruption of the cell 
monolayers could be the mechanism behind the increased Cd absorption rather 
than effects on TJs. Mannitol absorption was increased by both oleic acid and 
DHA and correlated with the decrease in TEER, without any pronounced cell 
toxicity. Mannitol is known to be entirely absorbed through the paracellular 
route (papers I and II). The increased paracellular permeability of the intestinal 
epithelium caused by oleic acid and DHA is a factor to consider in risk 
assessment. 57 
5.2.2  Aluminium and mannitol absorption across Caco-2 cell monolayers is 
increased by emulsions of oleic acid and DHA (paper II)   
In this paper it was hypothesized that Al followed the same pattern of 
absorption as mannitol, i.e. the paracellular pathway, and also that fatty acids 
like DHA and oleic acid increase the absorption of Al and mannitol through the 
paracellular pathway in Caco-2 cell monolayers. In a dose finding study, the 
apical to basolateral absorption of Al in Caco-2 cell monolayers was 
investigated after exposure for 90 min. A dose-dependent (0, 1, 2, 4, 10, 20 and 
30 mM Al) decrease in TEER starting at 2 mM Al was found, although the 
absorption of Al and mannitol did not increase significantly at concentrations 
up to 10 mM Al. At higher doses of Al (20 to 30 mM) the absorption 
increased, probably due to increased cell toxicity at these concentrations as 
evidenced by a considerably decreased TEER. A strong correlation between Al 
and mannitol absorption was found which confirms that Al similarly as 
mannitol is absorbed by the paracellular route. These findings are in line with 
previously published studies (Zhou & Yokel, 2005; Whitehead et al., 1997; 
Provan & Yokel, 1988). For further experiments with Al and fatty acids a 
concentration of 2 mM Al was chosen, since this concentration of Al had 
negligible effects on the Caco-2 cell monolayers with regard of LDH leakage 
and TEER.  
Emulsions of oleic acid (15 and 30 mM) and DHA (5 and 10 mM) 
increased the apical to basolateral absorption of Al and mannitol across Caco-2 
cells in a dose-dependent manner. A relation was seen between TEER and 
absorption across Caco-2 cell monolayers, i.e. when TEER decreased the 
absorption after 90 min exposure was concomitantly increased (figure 15). 
TEER decreased in all groups exposed to emulsions of fatty acids and Al, but 
only marginally in the 2 mM Al group, compared to the group exposed to Al-
free experimental medium. Al absorption was significantly increased in 
emulsions of 15 and 30 mM oleic acid and 10 mM DHA, while mannitol 
absorption was only significantly increased in emulsions of 30 mM oleic acid 
and 10 mM DHA. The results showed that TEER is decreased before Al and 
mannitol absorption is affected and without cytotoxic effects (fig 15 A and B). 
Thus, it is possible that pores between cells are only slightly affected by the 
fatty acids at low concentrations allowing passage of small ions without 
affecting Al and mannitol absorption. Another possible explanation is that TJs 
consists of pores with different sizes, and that only small pores are affected by 
exposure to low doses of fatty acids (Van Itallie et al., 2008; Watson et al., 
2005; Watson et al., 2001). 58 
 
Figure 15. Absorption of Al in Caco-2 cell monolayers after exposure of 2 mM Al-citrate  in 
emulsions of oleic acid (OA) or DHA for 90 min. (A) TEER at the end of exposure expressed as 
% of TEER before exposure. (B) Fractional absorption of Al and 
14C- mannitol expressed as % of 
apical dose (n= 6). 
a) Statistically significant in relation to Al-free experimental medium, P<0.05 
(Mann Whitney U-test). 
b) Statistically significant in relation to 2 mM Al-citrate in experimental 
medium. P<0.05 (Mann Whitney U-test). 
In morphology analysis with transmission electron microscopy (TEM) we 
found that cell monolayers exposed to Al-free experimental medium showed 
normal cell morphology with properly defined TJs and desmosomes (DS) 
(figure 16). Exposure of cells to emulsions of 30 mM oleic acid and 2 mM Al 
resulted in a less structured morphology of TJ and DS as well as of shorter 
microvilli. Cell-cell contacts were also less distinct and blurred. Thus, in this 
study our hypothesis that long-chained fatty acids compromise the TJs integrity 
causing an increased paracellular absorption of Al was supported.  59 
 
Figure 16. Morphological analysis of Caco-2 cell monolayers with transmission electron 
microscopy (TEM) showing a cross-section of a monolayer with apical microvilli, tight junction 
(TJ), desmosomes (DS) and other cell-cell contacts visible: (A) was exposed 90 min to Al-free 
experimental medium and (B) was exposed for 90 min to 2 mM Al-citrate in emulsion of 30 mM 
oleic acid. The bar represents 200 nm.  (Electron micrograph: Tapio Nikkilä) 
5.3  Oleic acid influence BCRP efflux of mitoxantrone, in vitro 
and in vivo (papers III and IV) 
5.3.1  The effect of oleic acid on BCRP-mediated  
efflux in vitro in Caco-2 cell monolayers (paper III) 
It was hypothesised that oleic acid influences the efflux function of BCRP and 
thereby increases the apical to basolateral absorption of MXR in Caco-2 cell 
monolayers. In a dose finding study it was found that absorption of MXR 
through the Caco-2 cell monolayers increased dose-dependently during 60 min 
exposure. The ratio between the MXR dose given apically and the amount 
retrieved on the basolateral side was not significantly different between groups, 
suggesting that there is no saturation of the efflux protein after exposure of 
MXR up to 1000 µM. No toxic effects on the monolayers were found, as 
measured by LDH and TEER. Thus, the cells tolerated rather high 
concentrations of MXR. However, 1 µM MXR was used in our Caco-2 cell 
experiments as this concentration has been used by other investigators and it is 60 
also in the same range as concentrations used in other experiments for 
inhibitors like Ko143 (Hubatsch et al., 2007; Matsson et al., 2007; Yamagata 
et al., 2007a).  
Apical to basolateral absorption of MXR was increased with increasing 
concentration of oleic acid (0.5, 1, 2, 4 and 5 mM) and also by the BCRP 
substrate cimetidine (figure 17a). Toxicity, as indicated by LDH leakage was 
only found in the highest dose group. TEER was only slightly decreased in 
groups exposed to 0.5 to 4 mM oleic acid, but markedly so in the 5 mM group. 
The increased absorption in the 5 mM oleic acid treated group could be due to 
an increase in paracellular absorption. However, in paper I and II we showed 
that emulsions of 15 mM oleic acid containing Ca
2+ did not increase absorption 
of mannitol, which is a paracellular marker. In addition, mannitol is a much 
smaller molecule than MXR and should therefore more readily be absorbed by 
the paracellular route. These previous findings strongly suggest that the effect 
of oleic acid on MXR absorption is due to the oleic acid effect on BCRP and 
not on the paracellular absorption. 
 The accumulation of MXR in the Caco-2 cells increases with increasing 
concentrations of oleic acid at doses of 2 mM or higher in our experiments. 
MXR absorption was also increased when cell monolayers were concomitantly 
exposed to MXR and the BCRP inhibitor Ko143, which further suggest that 
BCRP is involved in the restriction of MXR absorption in our Caco-2 cells 
(figure 17c).  
It was further investigated if pre-incubation of Caco-2 cell monolayers with 
oleic acid for 5.5 to 6 h influenced the oleic acid-dependent effect on MXR 
transport. In this experiment oleic acid was successively removed during and 
before the final MXR absorption experiment. Results showed that the increased 
absorption of MXR was not mediated by the presence of the oleic acid 
emulsion, since an increased MXR absorption persisted even after removal of 
the oleic acid emulsion (results not shown). 61 
 
 
Figure 17. Apical exposure of Caco-2 cell monolayers in (a) and (b) to 1 M MXR in emulsions 
of 0, 0.5, 1, 2, 4 and 5 mM oleic acid (OA) or 1 M MXR  and 0.1 mM cimetidine for 60 min. (a) 
MXR retrieved on the basolateral side, expressed as % of apical dose (median ± range) and in (b) 
MXR accumulated in cells after 60 min exposure, expressed as picomol/mg protein (median ± 
range). (c) Cells were exposed to 1 M MXR , 1 M MXR and 1 M Ko143 or 1 M MXR in 
emulsion of 1 mM oleic acid for 60 min and MXR was retrieved on the basolateral side, 
expressed as % of apical dose, n=5-6, median ± range. a) Statistically significant difference in 
relation to the group exposed to 1 M MXR, p<0.05 (Mann-Whitney U-test). 
It was also investigated if oleic acid had any influence on the gene expression 
of BCRP in Caco-2 cell monolayers. Results showed that oleic acid (1 mM) in 
culturing medium caused a significantly increased gene expression of BCRP 
after 6 hours exposure of Caco-2 cell monolayers (figure 18A). No effect could 
be seen after 1.5 h but after 3 and 9 h there was a tendency of increased gene 
expression due to the oleic acid exposure (figure 18A). However, Western blot 
quantification of the BCRP protein in the control group and the 1.5 and 6 h 
exposed groups did not show any differences between the groups (figure 18B).  62 
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Figure 18. (A) BCRP gene expression in Caco-2 cell monolayers exposed apically to 1 mM oleic 
acid for 1.5, 3, 6 or 9h in comparison with control monolayers exposed to DMEM for each time 
point. (B) Western blots of BCRP and tubulin in Caco-2 cell whole protein lysate. Control (C), 
Caco-2 cells treated with oleic acid (OA) for 90 min (90’) or 6 h, (n= 2-4). a) Statistically 
significant difference in relation to the controls at each time point, p<0.05 (Mann-Whitney U-
test). 
Taken together, the findings that oleic acid increases MXR absorption and the 
gene expression of BCRP, implicate that the effect of oleic acid on the 
transport of MXR is mediated by an inhibition of the function of the BCRP 
transporter. 
5.3.2  In vivo studies on mice (paper IV) 
The findings in paper III that oleic acid most probably inhibit the function of 
BCRP implicate that this also could happen in vivo. As a first step to verify 
these findings in vivo studies were carried out in male FVB mice. Oleic acid 
caused significantly increased levels of MXR in plasma, liver, kidney and brain 
at different time points (60 to 120 min) after the last oral dose of MXR in 
emulsions of oleic acid, when compared to respective time control (figure 19). 
The retention of MXR in the duodenum and upper part of jejunum was 
increased at 60 min after the last dose compared with controls.  
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Figure 19. Time dependency of MXR levels in tissues from male mice (FVB NCrl) treated orally 
with MXR and 
3H-MXR in emulsions of oleic acid. Samples from plasma, intestine, liver, kidney 
and brain were analyzed for 
3H-MXR, (n= 5-6). a) Statistically significant differences in relation 
to the timed control group exposed to 1 M MXR, p<0.05 (Mann-Whitney U-test). 
Furthermore, in a second experiment, levels of MXR were significantly 
increased in plasma, kidney and brain at all tested doses of oleic acid (0.6, 2.4 
and 4.8 g /kg). In liver MXR levels increased only after dosing of 2.4 g oleic 
acid/kg. In the duodenum and upper part of the jejunum, MXR levels increased 
only after 0.6 g oleic acid/kg (figure 20).  
However, no dose response was seen. This is in agreement with studies 
performed with surfactants like Pluronic 85 and Tween 20 given to mice 
simultaneously as the BCRP substrate topotecan, where the middle dose gave a 
more pronounced effect than the highest dose (Yamagata et al., 2007b). These 
authors suggested that surfactants may saturate the efflux pump competitively 
and thereby inhibit substrate binding to the efflux pump. Higher concentrations 
will thus not cause any further inhibition.  
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Figure 20. Dose-dependency of MXR absorption in tissues from male mice (FVB NCrl) treated 
orally with MXR and 
3H-MXR in emulsions of oleic acid. Samples from plasma, intestine, liver, 
kidney and brain were analyzed for 
3H-MXR, (n= 6). a) Statistically significant differences in 
relation to the group exposed to 1 M MXR, p<0.05 (Mann-Whitney U-test). 
Several studies have shown that surface active substances, like cremophor, 
PEG esters, polysorbates (e.g.Tween 20 and 80), polymers (e.g. Pluronic P85) 
similarly as oleic acid, negatively affects the function of  BCRP and thereby 
increase absorption of BCRP substrates in the intestine (Hirunpanich & Sato, 
2009; Wempe et al., 2009; Constantinides & Wasan, 2007; Yamagata et al., 
2007b).  
The increased absorption of BCRP substrates such as MXR, caused by oleic 
acid, might be due to several alternative mechanisms such as a) increased lipid 
solubility of the substrate, b) negative effects on the barrier function of TJs, c) 
direct influence on the function of BCRP, or d) indirect effects on its function, 
due to for instance alterations in the cellular membrane around the transporter 
or e) alterations in the energy availability for the transporters. In vitro (paper 
III), it was shown that oleic acid-induced increases in absorption of MXR were 
not due to an increased paracellular MXR absorption or increased lipophilicity 
of MXR. Thus, an effect on the BCRP is the most likely explanation to our 
observations. 
The ratio between plasma and tissue MXR concentrations in mice did not 
differ between the different time groups or the different dose groups (paper 
IV). This means that the effect on brain, kidney and liver accumulation is 
solely dependent on the plasma level. The increased levels in the brain could, 65 
in part, be due to the fact that the whole brain was sampled and not perfused, to 
get rid of residual blood in the tissue. However, when comparing the MXR 
levels in whole blood with the levels in the brain it was found that the brain 
contained more CPM than the blood on a volume/weight basis. Thus, the 
results suggest that the blood-brain barrier did not efflux MXR efficiently 
resulting in an increased uptake of MXR through the brain blood barrier when 
the blood MXR levels increased.  
Gene expression analyses with RT-PCR showed in our mouse experiments 
that BCRP was expressed in the intestine. However, no significant differences 
in BCRP gene expression in samples from jejunum were found. Nevertheless, a 
tendency towards an increase by time in gene expression was observed in the 
intestine from mice sacrificed 120 min after cessation of oleic acid treatment. 
This finding might indicate that BCRP gene expression in mice is influenced 
by oleic acid exposure.  
The dosing schedule used where oleic acid was given simultaneously as 
MXR three times during 1 h appeared to give robust results. In a study where 
oleic acid was given 30 min before MXR and the mice sacrificed 30 min after 
dosing, there was no increase of MXR in tissues or plasma (unpublished 
results). This suggests that the timing of contact between the intestinal 
epithelium and oleic acid and MXR is an important determinant for causing an 
effect.  
On a bodyweight basis, the doses given to mice were 2 to 7 times higher 
than the amount of free oleic acid that humans normally are exposed to through 
the diet. Nevertheless, we found that the lowest dose, twice the average intake 
in humans, increased MXR concentrations in plasma, brain, kidney and 
intestine in mice. In addition, the passage time of food in mice is faster than in 
humans which means that humans will be exposed during longer time periods 
for oleic acid and in that way oleic acid have the ability to affect human BCRP 
for longer time periods. 66 
6  Conclusions 
The impacts of fatty acids common in food on the absorption of substances  
relevant in a food contaminant perspective, i.e. cadmium and aluminium, have 
been investigated. The marker substances mannitol and mitoxantrone was used 
to study different absorption pathways in the intestinal epithelium. Mannitol 
are commonly used in studies of the paracellular pathway and MXR in studies 
of the efflux protein BCRP, preventing substances to be absorbed by the active 
transcellular pathway.  
DHA in physiologically relevant doses caused a significantly increased 
absorption of mannitol, Cd and Al through Caco-2 cell monolayers. Oleic acid, 
also in physiologically relevant doses, significantly increased the apical to 
basolateral absorption of mannitol and Al, but not Cd, through Caco-2 cell 
monolayers. TEER measured across the Caco-2 cell monolayer decreased as 
the doses of fatty acid increased. The strong relationship between changes in 
TEER and absorption of mannitol, Al and Cd clearly suggest that the increased 
absorption is due to increased paracellular absorption. Our findings were 
confirmed with morphological analyses with fluorescence microscopy and 
transmission electron microscopy. Thus, the paracellular absorption of poorly 
absorbed hydrophilic substances was found to be increased by oleic acid and 
DHA. 
Oleic acid decreased BCRP mediated efflux of MXR in Caco-2 cell 
monolayers, causing an increased absorption of MXR across the monolayers. 
Oral exposure of oleic acid to mice caused increased levels of MXR in blood, 
brain, kidney, liver and intestine. In addition, oleic acid up-regulated the BCRP 
gene expression in Caco-2 cell monolayers. These findings indicate that fatty 
acids in food inhibit the function of BCRP and thereby increase intestinal 
absorption of its substrates. The increased gene expression in vitro may be a 67 
compensatory reaction to the inhibition of BCRP mediated efflux. The effects 
of fatty acids on BCRP are important to consider in risk assessment of 
toxicants in food.  
In risk assessment of food toxicants the oral bioavailability is often assessed in 
laboratory animals that are generally kept on low-fat feeds compared with the 
human diet. Our findings that food components like fatty acids increase oral 
absorption of substances by different intestinal epithelial pathways, is an 
important finding that ought to be considered in future risk assessment. 
Consequently, risk based limits may be underestimated if they are based on 
animal studies using diets with low fat content.  
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7 Future  Perspectives 
In paper I we found that DHA but not oleic acid caused an increased 
absorption of Cd through Caco-2 cell monolayers. These findings would be 
interesting to verify in vivo. In such a study, DHA could be given together with 
radioactive labelled Cd to mice using the same dosing schedule as in paper IV, 
i.e. three times during one hour. The absorption of Cd may take place by 
different pathways through the intestinal epithelium. This could in fact be the 
reason why oleic acid did not increase Cd absorption even though it was shown 
in paper II that absorption of Al and mannitol were increased by oleic acid. The 
impact of DHA on transporter proteins essential for Cd efflux or absorption 
could be interesting to study in Caco-2 cells and also in mice.   
In paper II we showed that Al most probably was absorbed through the 
paracellular pathway and that oleic acid and DHA increased this absorption in 
Caco-2 cells. Whether this is true also in vivo can in fact be studied in humans. 
Al is included in antacid drugs used in humans. In an experiment, volunteers 
can be dosed with antacids containing Al according to the doses recommended 
for the medicine several times a day during 7 days, followed by sampling of 
urine and blood. After this dosing period a wash out period with no medication 
for 2 weeks can follow before sampling of blood and urine. After these two 
periods antacids containing Al could be given together with DHA in capsules 2 
to 3 times a day during 7 days, followed by sampling of urine and blood to 
investigate if the Al levels are higher after dosing with DHA. This experiment 
might give an answer if our findings in the Caco-2 cells are applicable also for 
humans.  
In paper III and IV we found that oleic acid increased absorption of the BCRP 
substrate MXR both in Caco-2 cell monolayers and in mice. The gene 
expression of BCRP was also increased by oleic acid exposure in Caco-2 cells. 69 
This indicated that oleic acid impairs the function of BCRP which may cause a 
compensatory up-regulation of the gene. The mechanism for this effect is not 
known. As both PPAR and PPAR nuclear receptors are activated by fatty 
acids and that it has been shown that BCRP is up-regulated by these receptors, 
it should be interesting to study the importance of oleic acid for the function of 
BCRP via its regulation through the PPAR and PPAR nuclear receptors. 
To finally support our hypothesis that fatty acids in food influence the oral 
absorption of BCRP substrates, studies in humans could be possible to do. 
Some BCRP substrates like folic acid and riboflavin are normally present in 
human tissues and are essential for many physiological processes in the human 
body. The influence of oleic acid on the absorption of folic acid could therefore 
be studied in humans. A similar procedure as for Al could be used. 
Development of resistance to drugs used as antimicrobials and anthelmintics is 
an emerging problem in the world. Resistance to the anthelmintics 
benzimidazoles used for treatment of e.g. liver flukes (fasciola hepatica) in 
animals and humans is an increasing problem (Brennan et al., 2007). Some of 
the benzimidazoles (triclabendazole, albendazole, oxfendazole) are known 
substrates and inhibitors of BCRP. Investigation of the effect of oleic acid on 
the efflux of benzimidazoles in worms might open for new treatment strategies 
to combat the development of resistance to benzimidazoles. Furthermore, 
several antibacterial substances have been shown to be substrates for BCRP 
e.g. ciprofloxacin, enrofloxacin, nitrofurantoin. The development of resistance 
to antimicrobials is also an increasing threat. One mechanism for development 
of antimicrobial resistance is that efflux transporters protect the 
microorganisms against accumulation of drugs. It would be interesting to study 
the effect of oleic acid on BCRP-mediated efflux of e.g. ciprofloxacin in 
bacteria. 
 
Finally, many food carcinogens are substrates for BCRP, which means that the 
absorption of them is normally restricted. The effect of oleic acid on the 
absorption of such substances, e.g. aflatoxin, in mice would be interesting to 
study. It could also be investigated if this increased absorption results in a 
higher mutagenic frequency in for instance the sensitive micronucleus tests in 
mice.  70 
8 Populärvetenskaplig  sammanfattning 
Denna avhandling handlar om fetters påverkan på tarmens förmåga att stoppa 
skadliga ämnen i mat att ta sig in till blodcirkulationen. Fett är livsnödvändigt 
för alla levande organismer inklusive människa. Det är ett av de viktigaste 
näringsämnena och behövs för en normal utveckling. Av den energi vi får i oss 
utgörs 30 – 40 % av fett. Mer än 90 % av fettet som vi får i oss från maten 
består av triglycerider som bryts ner till fria fettsyror och monoglycerider i 
mag-tarmkanalen. Fettsyrorna har en lipofil del (fettlöslig) bestående av en 
kolkedja av olika längd, och en hydrofil del (vattenlöslig) vilket ger dem 
ytaktiva egenskaper. Den vanligaste enkelomättade (en dubbelbindning i 
kolkedjan) fettsyran i maten är oljesyra (C18:1, 18 kol och 1 dubbel-bindning). 
Oljesyra förekommer rikligt i olivolja (55 – 83 %) och i fisk, avokado, nötter 
och flera andra vegetabiliska oljor. Fleromättade (flera dubbelbindningar i 
kolkedjan), så kallade omega- 3 fettsyror med kolkedjor som består av 18 eller 
fler kolatomer, anses vara viktiga för en mängd fysiologiska processer, bland 
annat inflammations-processer, immunsvar och celltillväxt. Dokosahexaensyra 
(DHA, C22:6, 22 kol och 6 dubbelbindningar) är en sådan fettsyra, som inte 
kan produceras i människans kropp och som därför är essentiell, d.v.s. är 
nödvändig att få i sig genom maten. DHA finns främst i fisk och skaldjur, men 
även i mjölk, ägg och lever, och säljs även som kosttillskott i form av kapslar.  
Det har länge varit känt inom läkemedelsforskningen att man kan öka 
absorptionen av läkemedel, som normalt absorberas dåligt i tarmen då de tas 
via munnen, genom att dosera dem tillsammans med ytaktiva ämnen. 
Dessutom har fettrika måltider visats öka absorptionen av vissa läkemedel som 
normalt absorberas dåligt.  
Det centrala i vår hypotes är att ytaktiva fettsyror som normalt finns i 
maten, oljesyra och DHA, har egenskaper som gör att de kan öka absorptionen 
av toxiska ämnen via maten.  71 
Tunntarmen är den plats där de flesta substanser absorberas för att komma 
in i blodcirkulationen. För att komma dit måste ämnet intas via munnen och 
därefter transporteras via matstrupen till magsäcken och sen vidare ner i 
tarmen. När substansen kommit till tunntarmen måste den passera flera 
barriärer innan den kan tas upp i blodet. I detta arbete har främst två 
absorptionsvägar undersökts.  
Först studerade vi den paracellulära absorptionen, vilken sker mellan tarm-
cellerna i det cell-lager som täcker tarmväggen, genom en barriär som kallas 
tight junctions (TJ). TJ är mycket täta och endast små vattenlösliga molekyler 
kan passera. Mannitol, som är en sockeralkohol, används ofta som 
modellsubstans då den absorberas uteslutande genom TJs.   
  Därefter studerade vi den transcellulära absorptionen. Substansen 
absorberas då genom tarm-cellerna med hjälp av transport-proteiner. 
Transport-proteiner kan antingen hjälpa substanser in i cellen och sedan ut i 
blodomloppet eller så kan de kasta ut substanser från cellen till tarminnehållet 
genom s.k. efflux. Många substanser som är intressanta ur ett 
livsmedelstoxikologiskt perspektiv hindras till viss del att komma in i blodet 
från tarminnehållet genom att de är s.k. substrat för efflux-proteinet 
BCRP/ABCG2 (breast cancer resistance protein). Exempel på sådana ämnen är 
stekytemutagenen PhIP, plastingrediensen bisfenol A, mykotoxinerna aflatoxin 
och ochratoxin, samt vissa läkemedel som används till livsmedelsproducerande 
djur och som kan ge upphov till resthalter i mat, t ex ivermectin, 
triclabendazol, albendazole och enrofloxacin. BCRP fungerar då som en barriär 
genom att kasta ut substanserna, tillbaka till tarminnehållet. Mitoxantron är ett 
läkemedel som används för behandling av bröstcancer och som ofta används 
som modellsubstans då man vill studera hur BCRP fungerar. BCRP finns i 
organ som är viktiga för absorption (tarmepitelet i tunntarmen), utsöndring 
(lever och njure) och fördelning (blod-hjärn-barriären, placenta barriären).  
I detta arbete har försök utförts, in vitro, genom att använda tarmepitelceller 
s.k. Caco-2 celler som ursprungligen kommer från en människa med colon- 
kancer. Då man odlar Caco-2 celler på filter som sätts i cellodlingsplattor, 
under ca 21 dagar, bildar cellerna ett tätt monolager av epitelceller med TJs 
och transportproteiner. Detta monolager av celler kan jämföras med ett 
tunntarmsepitel.  
I första delen av detta arbete var syftet att undersöka om oljesyra och DHA 
påverkar absorption av, de i livsmedel vanliga kontaminanterna, aluminium 
och kadmium via TJs i Caco-2 celler. Mannitol användes som modellsubstans 
för paracellulär absorption. Då cellerna exponerades för DHA samtidigt med 
aluminium, kadmium eller mannitol så ökade absorptionen av substanserna 
från den apikala (mot tarminnehållet) till den basolaterala (mot blodet) sidan av 72 
Caco-2 cellmonolagret i förhållande till om cellerna exponerades för 
substanserna utan DHA. Oljesyra påverkade bara absorptionen av aluminium 
och mannitol men inte kadmium. Detta innebär att den paracellulära 
absorptionen av dessa ämnen som normalt absorberas dåligt, ökar vid närvaro 
av fettsyrorna DHA och oljesyra. Elektronmikroskopiska bilder visar att 
tarmepitelet och även TJs påverkades negativt av DHA och oljesyra. Cell- cell-
kontakterna blev mer diffusa och inte så täta.  
I den andra delen av arbetet analyserades om oljesyra påverkar absorptionen 
av BCRP-substratet mitoxantron både i Caco-2 cell monolager och i mus. 
Oljesyra ökade absorptionen av mitoxantron från den apikala till den 
basolaterala sidan av Caco-2 cells-lagret. I mus ökade halten av mitoxantron i 
blod (serum) men också i tarm, lever, njure och hjärna då mössen gavs 
mitoxantron tillsammans med oljesyra. I mössen var oljesyrans effekt på 
absorptionen av mitoxantron tidsberoende vilket tyder på att absorptionen var 
beroende av hur lång tid oljesyran och mitoxantron låg kvar i tarmen. I 
cellförsöken undersöktes också om oljesyra påverkar genuttrycket av BCRP. 
Genuttrycket i Caco-2 celler ökade efter sex timmars exponering för oljesyra 
men mängden BCRP protein ökade inte. Något ökat genuttryck i tarm från mus 
kunde inte uppmätas troligen beroende på att exponeringstiden i möss var 
kortare än för cellerna. 
Våra resultat visar att fettsyror som normalt förekommer i mat ökar 
absorptionen av olika substanser över tarmen, vilken normalt hindrar 
substanserna att komma in i kroppen. Fettsyrorna verkade via två mekanismer, 
dels genom att vidga TJs och dels genom att hämma efflux-proteinet BCRP.  
Vid riskvärdering av kontaminanter i maten bör man ta hänsyn till att 
fettsyror i maten kan orsaka att ett ämne absorberas i högre grad än vad man 
förutsett i djurförsök. Laboratoriedjur äter mat med mindre fett än vad 
människor gör. Riskbaserade intagsgränser för toxiska ämnen i mat kan vara 
underskattade då de tagits fram med utgångspunkt från försök på 
laboratoriedjur, som har en diet med lågt fettintag.  
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